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Acetaminophen (APAP) overdose is a leading cause of acute liver failure (ALF) 
with limited treatment options. The mechanisms of APAP-induced liver injury include 
formation of a reactive metabolite N-acetyl-p-quinoneimine (NAPQI) and it’s covalent 
binding to protein, oxidative stress, mitochondrial damage and subsequent nuclear DNA 
damage leading to necrosis. The replacement of necrotic cells and restoration of liver 
function occurs through liver regeneration. Although several studies have shown that 
liver regeneration plays a crucial role in the final outcome of APAP-induced ALF 
patients, the mechanisms are not entirely known. DNA damage can activate the DNA 
damage response (DDR) – a signaling cascade that senses the damage and co-
ordinates cell cycle progression with DNA repair and other cellular processes. Although 
APAP toxicity involves severe nuclear DNA damage, role of DDR in regulation of liver 
regeneration after APAP induced acute liver injury ALI has not been investigated. My 
hypothesis is that the DDR and p53- a DDR effector protein which induces cell cycle 
arrest, are activated after APAP overdose and connect liver injury response to initiation 
of liver regeneration.  
We studied DDR using incremental dose model with two different doses of APAP 
in mice [300 mg/kg (APAP300)-a regenerative dose and 600 mg/kg i.p. (APAP600)-a 
non-regenerative dose]. We began by analyzing microarray data obtained from the 
incremental dose model using the Ingenuity Pathway Analysis program. This analysis 
revealed significant differences in DNA damage, replication and checkpoint related 





overdose causes DNA Double Strand Break (DSB) in both groups of animals and it is 
sustained in mice treated with APAP600 relative to mice treated with APAP300. We 
also observed a subsequent increase in DNA repair proteins in APAP300 treated mice 
but not in APAP600 treated mice. The DNA repair pathway was significantly suppressed 
and p53 activation was significantly higher in mice treated with APAP600 as compared 
to APAP300. These data illustrate that delayed DSB repair response occurs after APAP 
overdose leading to prolonged growth arrest and may be a crucial mechanism involved 
in inhibition of liver regeneration. 
Next, we investigated roles of p53 in detail using WT and p53KO mice (C57BL/6J 
background) following APAP300 treatment. Remarkably, deletion of p53 resulted in a 3-
fold higher liver injury when compared to WT mice implying a protective role for p53 in 
injury progression. Deletion of p53 did not affect APAP bioactivation however it delayed 
clearance of APAP protein adducts from liver. Intriguingly, despite higher injury p53KO 
mice recovered similarly as the WT mice due to faster liver regeneration. Global 
transcriptomic and molecular analysis revealed several mechanisms triggering higher 
progression of liver injury yet faster regeneration in p53KO animals after APAP300 
treatment. Impaired metabolic homeostasis, GSH transsulfuration and reduced 
expression of mitochondrial complexes in p53KO mice resulted in higher liver injury. 
However, increased inflammatory signaling and proliferative signaling through AKT, 
ERK and mTOR pathways improved recovery in p53KO mice despite very high injury. 
These studies show that p53 plays a pleotropic role after APAP overdose where it 





homeostasis and also regulates initiation of liver regeneration through inflammatory and 
proliferative signaling. 
Overall, my studies comprehensively investigated roles of DDR and p53 in liver injury 
and regeneration after APAP overdose. These studies have uncovered novel 
mechanisms that connect cellular injury to initiation of liver regeneration after APAP-
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1.1  ACUTE LIVER FAILURE (ALF) 
Acute Liver Failure (ALF) is a clinical syndrome characterized by rapid onset of 
severe hepatocyte injury and associated with coagulopathy and encephalopathy in a 
patient without preexisting liver disease (Lee 1993, Hoofnagle, Carithers et al. 1995). 
The signs or symptoms associated with ALF are hepatic dysfunction, abnormal liver 
biochemical values, coagulopathy and encephalopathy, culminating in multiorgan failure 
(Lee 2012). ALF is the result of severe liver cell injury from a variety of different 
etiologies, such as neoplastic infiltration, acute Budd–Chiari syndrome, heatstroke, 
mushroom poisoning, Wilson’s disease, ischemic hepatocellular injury, viral infections, 
drug induced liver injury and idiosyncratic drug reactions (Bernal and Wendon 2013). In 
developing countries, viral infections (hepatitis A, B, and E) and drug induced liver injury 
(especially that of anti-tubercular drugs) are main causes of ALF. However, in the 
Western world, overdose of the commonly used analgesic and antipyretic agent 
acetaminophen (APAP) is the major cause of ALF accounting for nearly 50% of all ALF 
cases in the US, 70% in the UK, 40% in Sweden and 15% in Germany (Ellis 1998, 
Ostapowicz, Fontana et al. 2002, Bernal 2003, Larson, Polson et al. 2005, Wei, 
Bergquist et al. 2007, Bernal and Wendon 2013).  
 
1.2  ACETAMINOPHEN TOXICITY 
Acetaminophen (APAP) is the widely used analgesic and antipyretic drug 
(Kaufman, Kelly et al. 2002). It is an active ingredient in more than 600 over the counter 





considered safe at recommended doses however overdose of APAP causes severe 
liver injury, which can develop into ALF. Annually over 78,000 emergency room visits, 
33,000 hospitalizations and around 500 deaths have been reported due to APAP 
overdose in the USA (Budnitz, Lovegrove et al. 2011, Manthripragada, Zhou et al. 
2011). A daily dose of 4g is the maximum recommended dose with margin of safety 
(Watkins, Kaplowitz et al. 2006). However, intake of APAP exceeding the limit of 4g has 
been observed in intentional and unintentional overdose due to concomitant use of 
multiple medications containing APAP leading to Acute Liver Injury (ALI). Likewise, 
combination medicines containing opiates with APAP also increase risk of liver injury 
(Budnitz, Pollock et al. 2006).  
At therapeutic doses, majority of APAP is metabolized in the liver by UDP- 
glucuronosyl transferase (UGT) and Sulfotransferase (SULT) accounting for 50-70% of 
APAP-glucuronide and 25-35% APAP-sulfate metabolites excreted in urine. About 2% 
of ingested APAP is excreted unchanged in urine (Fig.1.2.1). Only 5-15% of APAP is 
metabolized by Cytochrome P450 enzymes to reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI) that reacts with cellular glutathione (GSH) spontaneously 
or in presence of glutathione S-transferase (Miner and Kissinger 1979). APAP-GSH as 
cysteine conjugate is excreted in bile and then in urine (Cummings, King et al. 1967, 
McGill and Jaeschke 2013).  
After APAP overdose excess NAPQI is formed, which far exceeds the amount of 
cellular GSH and extra free NAPQI then reacts with protein sulfhydryl groups to form 





proteins compromises mitochondrial respiration, stops ATP production and generates 
oxidative (ROS) as well as nitrosative (RNS) stress in mitochondria leading to initiation 
of the liver cell injury (Jaeschke, Knight et al. 2003, Jaeschke, McGill et al. 2012). These 
initiating events require further amplification and propagation to cause cell death, which 
is caused by a cascade of kinase-mediated signaling. The most prominent of these is 
activation of c-Jun N-terminal kinase (JNK), and Rip1/3 kinase (Hanawa, Shinohara et 
al. 2008, Ramachandran, McGill et al. 2013). Mitochondrial oxidative stress causes 
activation of mitogen activated protein kinase (MAPK) and apoptosis signal regulating 
kinase 1 (ASK1) which in turn activates JNK (Nakagawa, Maeda et al. 2008). Activated 
JNK translocates to mitochondria and further enhances mitochondrial ROS generation. 
Mitochondrial ROS causes mitochondrial DNA damage, BAX translocation to 
mitochondria, opening of mitochondrial permeability transition pore (MPT) resulting in 
collapse of membrane potential and decreased ATP production. These events result in 
mitochondrial swelling and rupture with release of endonuclease G and AIF. Both these 
proteins translocate to nucleus and cause massive nuclear DNA fragmentation and 
eventually hepatocyte necrosis (Kon, Kim et al. 2004, Jaeschke and Bajt 2006, 












Fig. 1.2.1 Schematic of APAP metabolism. Most of ingested APAP is metabolized by 
glucuronidation and sulfation. Very small fraction of APAP is bioactivated by 
Cytochrome p450 2E1 enzyme (CYP2E1) to N-acetyl-p-benzoquinone imine (NAPQI). 
NAPQI can be detoxified by glutathione (GSH) or form protein adducts. All conjugated 







During hepatocyte necrosis due to APAP overdose, various damage- associated 
molecular patterns (DAMPs) such as nuclear DNA fragments and HMGB1 are released. 
These DAMPs activate Kupffer cells (KCs) through TLR receptors leading to increased 
cytokine and chemokine production (Jaeschke, Williams et al. 2012). Pro-inflammatory 
cytokines and chemokines such as IL1β, TNFα, and MCP1 activate and recruit 
neutrophils and monocytes to the liver (Williams, Farhood et al. 2010). Monocyte-
derived M2 macrophages get recruited to the liver and secrete anti-inflammatory 
cytokines such as IL10. These activated phagocytes can facilitate removal of dead cells 
from liver and initiate wound healing process (Bourdi, Masubuchi et al. 2002, Woolbright 
and Jaeschke 2017).  Several studies have indicated role of inflammatory mediators 
such as vascular endothelial growth factor (VEGF), IL6, and TNFα in promoting liver 
regeneration after an APAP induced liver injury as well (Chiu, Gardner et al. 2003, 
James, Lamps et al. 2003, Donahower, McCullough et al. 2006, Kato, Ito et al. 2011). 
 
1.3  LIVER REGENERATION – A PLAUSIBLE THERAPY FOR 
ACETAMINOPHEN TOXICITY 
Therapeutic intervention for ALF is a challenge because of its rapid progression, 
few treatment options and frequent bad outcomes. APAP overdose is a major cause of 
ALF in the Western world however, therapeutic options for APAP-induced ALF are 
extremely limited. At present, N-acetylcysteine is the only antidote for APAP and shows 
maximum efficacy when given within 8-10 h of overdose (Larson 2007, Fontana 2008, 





thereby scavenge NAPQI and prevents toxicity at early stage. At later stages, NAC 
treatment is less effective. However, it still improves oxidative stress by facilitating GSH 
synthesis and, in mitochondria, supports mitochondrial energy metabolism (Smilkstein, 
Knapp et al. 1988, Larson 2007, Saito, Zwingmann et al. 2010). Another treatment 
option is liver transplantation for patients who progress to ALF. However, only 25-30% 
ALF patients get liver transplants due to lack of donor organs (Lee 2012). Currently, 
around 14,000 patients are on liver transplant waitlist. Moreover, life-long 
immunosuppression further complicates patients’ post-transplant existence. 
Several studies have underlined the importance of enhanced liver regeneration 
following toxic chemical induced liver injury including APAP in improving final outcome 
in rodents and humans (Mehendale 2005, Jaeschke and Bajt 2006, Apte, Singh et al. 
2009, Bhushan, Walesky et al. 2014). Various signaling mediators have been identified 
that prevent progression of liver injury and promote tissue repair following APAP 
induced toxicity. For instance, IL6 KO mice exhibited prolonged liver injury accompanied 
by inhibited liver regeneration. Pretreatment with IL6 in these mice improved liver injury 
and restored liver regeneration following APAP toxicity(James, Lamps et al. 2003). Loss 
of TNFR1 and VEGFR1 in mice reduced hepatocyte proliferation and contributed to 
exaggerated liver injury following APAP toxicity (Chiu, Gardner et al. 2003, Donahower, 
McCullough et al. 2006, Kato, Ito et al. 2011). Whereas, treatment with human 
recombinant VEGF in WT mice prevented progression of liver injury and improved liver 
regeneration (Donahower, McCullough et al. 2010). Two independent studies have 
found importance of stem cell factor (SCF) and its receptor c-kit (progenitor cell marker) 





and Colletti 2008). Depletion of SCF in mice with antibody or genetic deletion increased 
liver injury and mortality whereas SCF treatment increased hepatocyte proliferation and 
improved survival after APAP toxicity (Simpson, Hogaboam et al. 2003, Hu and Colletti 
2008). The role of liver regeneration in favorable outcome (survival without transplant) 
has also been demonstrated in patients. Two retrospective studies using APAP 
overdosed patient samples identified elevated α-fetoprotein (AFP) levels and 
hypophosphatemia as an indicator of patient survival and correlated results with 
improved liver regeneration in those patients (Schmidt and Dalhoff 2002, Schmidt and 
Dalhoff 2005).  
Further, two reports correlated increased β-catenin activation with cell cycle 
progression and higher liver regeneration (Apte, Singh et al. 2009, Bhushan, Walesky et 
al. 2014). Bhushan et al. used incremental dose model in mice with 300 and 600 mg/kg 
APAP dose. In this model, mice treated with 300 mg/kg APAP showed liver injury 
accompanied by compensatory increase in regeneration, while mice treated with 600 
mg/kg APAP showed injury progression and significantly inhibited liver regeneration. 
APAP600 animals showed reduced activation of Wnt/β-catenin pathway, a pro-
regenerative mechanism, and sustained activation of cell cycle inhibitor p21, anti-
proliferative mechanism. Next, β-catenin overexpression in mice improved liver 
regeneration following APAP600 dose. Another study using a GSK 3 inhibitor increased 
activation of β-catenin signaling and liver regeneration following APAP600 treatment in 
mice (Bhushan, Poudel et al. 2017). These studies highlighted importance of active β-






These studies emphasize that stimulating liver regeneration in APAP-induced 
ALF patients is a plausible therapeutic option. However, mechanisms that regulate liver 
regeneration are not entirely known. Studying these mechanisms will provide better 
understanding of the dynamics of liver regeneration and may lead to improved 
therapeutic intervention for ALF patients. 
 
1.4  DNA DAMAGE RESPONSE (DDR) AND ITS ROLE IN APAP 
TOXICITY  
Cellular DNA is constantly subjected to assault from exposure to endogenous 
(e.g. metabolic ROS, replicative stress) and environmental (e.g. chemicals, radiation) 
stress (Kawanishi, Hiraku et al. 2006, Valko, Rhodes et al. 2006). Estimations suggest 
that a cell could experience up to 105 DNA lesions per day due to various insults 
(Lindahl and Barnes 2000). The maintenance of DNA integrity and stability is an 
essential task to both cellular function and survival, as uncorrected insult could cause 
mutation and possibly a disease. To efficiently manage DNA damage resulting from 
various insults, a broad cellular response is elicited and it is referred to as DDR. DDR is 
an integrated signaling network that senses DNA damage, replication stress and 
transduces this information to induce protective mechanisms in the cell and influence 
cellular responses to DNA damage (Fig. 2). In response to DNA damage, the pathways 
of DDR co-ordinate cell cycle progression with DNA repair, chromatin remodeling, 
transcriptional programs and other metabolic adjustments including cell death (Zhou 





categorized in four groups including damage sensors, signal transducers, mediators 
and outcome effectors. The sensor proteins such as PARP sense the DNA damage and 
generate signals in order to recruit and activate transducer proteins. These signals are 
amplified and propagated by transducers such as kinases (ATM, CHK1) and mediator 
proteins (53BP1, H2AX). This initiates a signaling cascade to co-ordinate effector 
proteins such as p53 (Sulli, Di Micco et al. 2012). Mediator proteins can also recruit 
DNA repair effector proteins to the damaged DNA site, which are responsible for 







Fig.1.4.1. Schematic representation of double strand break DNA damage 
signaling and repair pathway. After detection of DNA damage by sensor proteins 
(PARP, MRN, DNAPKc), this signal is amplified and diversified by multiple transducer 
proteins (ATM, ATR, CHK1, CHK2) to mediator proteins (53BP1, H2AX, BRCA1) and 
effector proteins (DNA repair proteins and p53). These downstream effector proteins 
regulate various cellular functions (DNA repair, cell cycle arrest, senescence, cell death) 
PARP: PolyADPribose polymerase, MRN : Mre11 RAD500 NBS1 complex, DNAPKcs: 
DNA dependent protein kinase catalytic subunit, ATM: Ataxia telangiectasia mutated, 
ATR: ATM related, CHK1, CHK2: Checkpoint kinase 1 and 2, 53BP1: p53 binding 






APAP toxicity involves a sequential chain of events beginning with formation of a 
reactive metabolite (NAPQI), increased ROS, mitochondrial damage, nuclear DNA 
fragmentation and necrotic cell death. To compensate for necrotic cell death, 
hepatocytes undergo proliferation and the liver regenerates following APAP toxicity. 
However, if severe DNA fragmentation, ROS or replicative stress after APAP overdose 
can elicit DDR is not well studied. Previously, one study showed that APAP causes 
increased phosphorylation of histone H2AX at Ser 139 as a marker of DNA double 
strand break in inner medullary collecting duct (p1rIMCD) cells. Increased toxicity of 
APAP when combined with caffeine in p1rIMCD cells was speculated due to inhibition of 
DNA damage repair (Cai, Dmitrieva et al. 2003). Several studies have investigated role 
of DDR sensor protein PARP in pathophysiology of APAP overdose (Shen, Kamendulis 
et al. 1992, Kroger, Dietrich et al. 1997, Cover, Fickert et al. 2005). PARP1 is activated 
after APAP mediated DNA damage and its activation did not contribute to APAP toxicity 
in mice (Cover, Fickert et al. 2005). However, involvement of PARP in DNA repair and 






1.5  DOUBLE STRAND BREAK (DSB) REPAIR AND ITS ROLE IN 
APAP PATHOPHYSIOLOGY 
DNA lesions that elicit the DDR can be classified based on structural 
manifestation including single strand break (SSB) and double strand break (DSB). 
These can be further classified based on chemical nature of insult as bulky adduct 
formation, base mismatch, base insertion or deletion, base alkylation, base oxidation. 
Repair mechanisms are specific to the type of lesion and the phase of the cell cycle. 
The most subtle changes, such as oxidative lesions, alkylation and SSBs are repaired 
through the base excision repair (BER) mechanism. Missmatch repair (MMR) replaces 
mispaired DNA bases with correct bases. Bulkier DNA single strand lesions are 
repaired through the nucleotide excision repair (NER) mechanism (Polo and Jackson 
2011, Lord and Ashworth 2012). DSB is considered the most deleterious lesion and is 
repaired through non-homologous end joining (NHEJ) at all phases of the cell cycle or 
through homologous recombination (HR) during S and G2 phases (Chapman, Taylor et 
al. 2012). During HR, an undamaged copy of DNA that shares sequence homology with 
broken DNA is used to repair the break. In contrast, NHEJ ligates two broken DNA 
ends, without the requirement for sequence homology (Jackson 2002).  
DDR following DNA DSB involves post-translational modifications of histones 
and histone-binding proteins near damaged site. The earliest modification is Poly(ADP-
ribosyl)ation (also called PARylation) of lysine residues in histones, binding of chromatin 
modifiers NuRD (nucleosome remodeling and deacetylase) and polycomb complexes to 





activity of the RING finger protein 8 (RNF8) and RING finger protein 168 (RNF168) 
ubiquitin ligases, which are also implicated in DNA repair (Ciccia and Elledge 2010, 
Bekker-Jensen and Mailand 2011, Polo and Jackson 2011). Another important histone 
modification and a hallmark of DSB is phosphorylation of histone H2AX on Ser139 
(γ-H2AX) by apical kinases such as ATM, ATR, DNAPkcs. This event is followed by 
dephosphorylation of the Tyr142 residue by EYA phosphatse. The Tyr142 residue on 
H2AX is constitutively phosphorylated by WSTF kinase in the absence of damage. 
Dephosphorylation of Tyr142 is required for binding of MDC1- sensor protein, to 
γ-H2AX (Cook, Ju et al. 2009, Xiao, Li et al. 2009). Further MDC1 and NBS1 anchor 
activated ATM spreads H2AX phosphorylation to adjacent nucleosomes. Activated ATM 
also phosphorylates MDC1, which triggers recruitment of RNF8, to initiate an 
ubiquitylation cascade, which is amplified by RNF168. This facilitates the recruitment of 
genome caretakers such as BRCA1, RAP80, RAD18, PTIP, 53BP1 etc. (Lukas, Lukas 
et al. 2011). BRCA1 recruitment at DSB site favors the repair through HR while 53BP1 
favors NHEJ. DNA end resection is another important deciding factor for DSB repair 
pathway choice as it is required for homology searching during HR.  CtIP mediates end 
resection. Interaction of CtIP with BRCA1 and its end resection activity is dependent on 
CDK1 mediated phosphorylation, which is higher during S and G2 phase of cell cycle. In 
contrast, during G1 phase 53BP1 and RIF1 inhibit BRCA1 recruitment to DSB site, 
hence favoring the NHEJ pathway. 53BP1 also prevent the 5’ end resection and hence 
promote the binding of Ku70/Ku80 flanking the DSB (Zhou and Elledge 2000, 











Fig. 1.5.1 Schematic showing initiation of DSB repair. Following DNA DSB histone 
H2AX get phosphorylated at Ser139 (γ-H2AX) and chromatin modulators (PARP, 
NuRD) modifies chromatin favorable to DNA repair. EYA phosphatase dephosphorylate 
H2AX-Tyr 142 residue and ATM amplifies γ-H2AX. Binding of MDC1 and RNF8/168 
mediated ubiquitination facilitate recruitment of 53BP1 (during all cycle phases) or 
BRCA1 (during S/G2 phase). 53BP1 binding mediates NHEJ repair while BRCA1 
mediates HR repair. PARP: PolyADPribose polymerase, PARylation: Poly ADP 
Ribosylation, NuRD: nucleosome remodeling and deacetylase complex, EYA: Eyes 
Absent phosphatase, MDC1: Mediator of DNA Damage Checkpoint 1, RNF8,168: Ring 
Finger Protein 8, 168, ATM: Ataxia Telangiectasia Mutated, 53BP1: p53 binding protein, 
BRCA1: Breast Cancer 1 protein, RIF1: Replication Timing Regulatory Factor 1, CtIP: 










1.5.1  NONHOMOLOGOUS END JOINING REPAIR PATHWAY 
During NHEJ, Ku70/80 heterodimer detects and binds to the extreme termini of 
the DSB through its high affinity for double stranded DNA ends. It is required to 
propagate signal to the subsequent NHEJ factors (Fig. 3). Binding of the KU 
heterodimer facilitate recruitment of a serine threonine protein kinase - DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), of the phosphatidyl inositol 3-kinase-like 
protein kinase (PIKK) family. DNA-PKcs and Ku form a holoenzyme and hold 
juxtaposed DNA ends in a complex. Formation of the holoenzyme enhances DNA PKcs 
kinase activity, leading to phosphorylation of several NHEJ associated proteins 
including KU70, KU80, XRCC4, XLF, Artemis, and LIG4 (Hartlerode and Scully 2009). 
These factors then process the juxtaposed DNA ends while repairing the DSB. If the 
DSB results in non-ligatable ends containing 3’ phosphate, 3’ phosphoglycolate or 5’ 
hydroxyl etc., these must be converted to 3’ hydroxyls and 5’ phosphates or removed. 
Polynucleotide kinase/phosphatase (PNKP), a DNA 3’ phosphatase/5’ kinase processes 
these non-ligatable ends before ligation. Nucleases such as exonuclease 1(Exo1) and 
Artemis may trim the 3′ and 5′ single-stranded overhangs to reveal DNA sequence 
microhomology (Ma, Pannicke et al. 2002). After DNA end processing any short 
nucleotide gaps are filled by DNA polymerases μ and λ by adding nucleotides. X-ray 
cross-complementing gene 4 (XRCC4) and XRCC4-like factor (XLF or Cernunnos) don’t 
have catalytic activity but interact with PNKP and DNA ligase IV (LIG4). Once 





complex containing XRCC4 and XLF (Zhou and Elledge 2000, Rothkamm, Kruger et al. 
2003, Lieber 2010, You and Bailis 2010, Polo and Jackson 2011). 
Finally, γ-H2AX must be dephosphorylated once the DNA is repaired to restore 
the genome. During DDR signaling cascade effector protein p53 gets activated which 
halts the cell cycle while damaged DNA is repaired. WIP1 phosphatase is a target of 
p53 and it dephosphorylates γ-H2AX (Moon, Nguyen et al. 2010). WIP1 can also 
dephosphorylate MDM2 and facilitate MDM2 mediated p53 ubiquitination and 
degradation. WIP1-p53-MDM2 form a feedback mechanism to terminate the DDR. 
In response to partial hepatectomy (PHX) or liver injury, remaining hepatocytes 
undergo cell division rapidly. That increases DNA replication associated risk of DNA 
damage (Saintigny, Delacote et al. 2001). A recent study has shown that genetic 
deletion of nucleostemin in mice results in increased DNA double strand breaks in 
regenerating liver following PHX (Lin, Ibrahim et al. 2013). However there is no 
investigation done to study role of DNA damage in liver regeneration following APAP 






Fig.1.5.1.1. Schematic representation of Double strand break repair by NHEJ 
pathway. DNA repair process is initiated by binding of 53BP1 (p53 binding protein 1) at 
DNA ends then recruiting Ku70/80 and two DNA-PKCS (DNA dependent protein kinase 
catalytic subunit) molecules. Activated DNA PK help recruit proteins involved in DNA 
end processing e.g. Artemis, PNKP (Polynucleotide kinase 3’ phosphatase) to form 
ligatable termini.  The break is then repaired by the Lig4(ligase 4), XRCC4(X-ray repair 






1.6  P53 AND ITS ROLE IN APAP PATHOPHYSIOLOGY 
DDR pathway coordinates cell cycle checkpoint activation and DNA repair 
proteins by arresting the cell cycle, thus allowing time for repair processes. The key 
effector protein that co-ordinate these processes is p53.  It plays a critical role in 
deciding cell fate following DNA damage. Widely known as the “cellular gatekeeper”, 
p53 is a tetrameric transcription factor which binds as dimers of dimers to sequence-
specific p53 response elements and stimulates or represses transcription of many 
protein-coding and non-protein-coding genes including microRNAs and lincRNAs 
(McLure and Lee 1998, He, He et al. 2007). Cellular levels of p53 are primarily 
controlled by mouse double minute protein 2 (MDM2) through its ubiquitin-mediated 
proteasomal degradation (Haupt, Maya et al. 1997, Levine and Oren 2009). However, 
activity of MDM2 is inhibited by several mechanisms including ARF interference of 
Mdm2-p53 interaction, ATM, c-Abl mediated phosphorylation, and CBP/p300-mediated 
acetylation that results in increased p53 levels (Kruse and Gu 2009, Shi and Gu 2012). 
p53 is stabilized by several post-translational modifications. In response to stress, more 
than 36 amino acids in p53 are post-translationally modified by phosphorylation, 
ubiquitination, acetylation, methylation, sumoylation, glycosylation or ribosylation 
(DeHart, Chahal et al. 2014). All these post-translational modifications lead to 
stabilization, accumulation and activation of p53 transcriptional function. After DNA 
damage Ser-15 and Ser-20 residues of p53 are phosphorylated by a number of kinases 
including ATM, ATR, DNAPKc, Chk1, Chk2(Kastan and Lim 2000, Ou, Chung et al. 





interaction with MDM2 inhibiting its ubiquitination and degradation. Stabilized p53 binds 
to p53 response elements in the presence of co-activators or co-repressors and 
regulates target gene expression. Following DNA damage, the activated p53 triggers 
cell cycle arrest until damaged DNA is repaired. If the DNA damage is beyond repair, 
p53 can induce cell senescence or apoptosis (Haupt, Berger et al. 2003, Carvajal and 








Figure 1.6.1 Schematic of p53 activation pathway. During normal conditions, p53 is 
degraded through MDM2 mediated ubiquitination. Stress induces stabilaization of p53 
by ATM, CHK and other kinases mediated phosphorytion that results in activation or 









In recent years a significant number of p53 responsive genes have been 
identified, which respond to various forms of cellular stresses including DNA damage, 
ROS, metabolic homeostasis (Kruiswijk, Labuschagne et al. 2015). p53 target genes 
involved in various cellular processes are listed in Table 1.6.1. The functions of p53 
have been primarily studied in tumor models and cultured cancer cell lines. Although 
numerous studies have shown role of p53 in various pathophysiological conditions 
beyond cancer e.g. development, aging, obesity, diabetes, its role in compensatory cell 
proliferation after drug-induced liver injury is not known.  
Previous studies in rodents using partial hepatectomy model have depicted a role 
of p53 in regulation of ploidy and cell proliferation during liver regeneration (Stepniak, 
Ricci et al. 2006, Kurinna, Stratton et al. 2010, Kurinna, Stratton et al. 2013, Jin, Hong 
et al. 2015, Zhang, Liu et al. 2015). p53 controls cell proliferation by binding a p53RE 
near FOXO3 transcription start site and maintains active expression of Foxo3 - a cell 
proliferation inhibitor - in quiescent mouse liver. However, during liver regeneration in 
mice following PHX, p53 binding and expression of Foxo3 is reduced (Kurinna, Stratton 
et al. 2010). Further, deletion of p53 rescues liver regeneration in mice lacking c-jun in 
liver, suggesting role of p53 in inhibiting liver regeneration (Stepniak, Ricci et al. 2006). 
In contrast, mice with C/EBPα-S193A mutation and low p53 expression failed to stop 
liver regeneration following PHX (Jin, Hong et al. 2015). As discussed in Chapter 1.5.1 
WIP1 phosphatase is a target of p53. WIP1 can dephosphorylate MDM2 and facilitate 
MDM2 mediated p53 degradation results in feedback loop formation. Wip1 KO mice 
showed higher liver regeneration despite p53 expression and p53 deletion in Wip1 KO 





regeneration (Zhang, Liu et al. 2015). Furthermore, p53KO mice fail to resolve 
polyploidy following PHX (Kurinna, Stratton et al. 2013).  
A recent study showed that deletion or chemical inhibition of p53 increases 
APAP toxicity in mice indicating protective role of p53 in pathophysiology of APAP 
overdose (Huo, Yin et al. 2017). Previous studies using in vitro and in vivo models of 
APAP overdose have indicated a protective role of p53 in pathophysiology of APAP 
toxicity (Stamper, Garcia et al. 2015). Whereas these studies indicated that p53 may 







Table 1.6.1. Representative p53 target genes 
Cellular Processes P53 Target Genes 
Cell Cycle Arrest GADD45, p21, BTG2, mir34 
Senescence p21, PAI1, PML 
Apoptosis BAX, Survivin, PUMA 
DNA repair GADD45, DDB2, RRM2 
Metabolic Homeostasis SCO2, AMPK, PFK 
ROS clearance GPX, MnSOD, Sestrin, ALDH4, GAMT 







1.7  PARP AND ITS ROLE IN APAP PATHOPHYSIOLOGY 
Poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) is a stress sensor and a stress 
response mediator protein (Luo and Kraus 2012, Filomeni, De Zio et al. 2015). PARP-1 
uses NAD+ to add ADP ribose units in PAR polymers on nuclear proteins such as 
histones, DNA repair proteins, transcription factors, and chromatin modulators (Kraus 
2008, Luo and Kraus 2012). PAR glycohydrolase (PARG) hydrolyzes the covalently 
attached polymers to free PAR or mono(ADP-ribose). PARP-1 can bind to intact and 
damaged DNA. It is activated during genotoxic stress facilitating DNA repair, chromatin 
modification, and transcription. In the presence of low DNA damage, PARP1 functions 
as a survival factor, PARylates and remodels DNA damage. Hyperactivation of PARP 
depletes NAD+ levels and subsequent cellular ATP resulting necrotic cell death 
(Swindall, Stanley et al. 2013, Weaver and Yang 2013).  
The role of PARP has been studied in DNA repair after arsenic toxicity. Studies 
show that arsenite directly inhibits PARP enzyme activity and prevents DNA repair, 
leading to toxicity (Sun, Zhou et al. 2014, Luo, Li et al. 2015). Previous studies show 
that PARP is activated within 6-12 hours after APAP overdose in mice and PARP 
activation was believed to play role in promoting injury. However, PARP inhibition using 
PARP KO mice or specific PARP inhibitor do not prevent APAP mediated liver injury. In 
fact, PARP KO developed exaggerated injury when compared to WT mice, suggesting a 
protective role in injury development after APAP overdose (Cover, Fickert et al. 2005). 






1.8  STATEMENT OF PURPOSE 
Overdose of APAP is the cause of almost 50% of all ALF cases in the US, 70% 
in the UK, 40% in Sweden and 15% in Germany (Ellis 1998, Ostapowicz, Fontana et al. 
2002, Bernal 2003, Larson, Polson et al. 2005, Wei, Bergquist et al. 2007, Bernal and 
Wendon 2013). Despite being the major cause of ALF in Western world, therapeutic 
options for APAP induced ALF are extremely limited. There is a critical need to develop 
novel therapeutic strategies for APAP induced ALF cases. Recent studies using 
experimental models and ALF patient samples demonstrated that liver regeneration is a 
critical determinant of final outcome (Schmidt and Dalhoff 2002, Chiu, Gardner et al. 
2003, James, Lamps et al. 2003, Simpson, Hogaboam et al. 2003, Schmidt and Dalhoff 
2005, Donahower, McCullough et al. 2006, Hu and Colletti 2008, Apte, Singh et al. 
2009, Donahower, McCullough et al. 2010, Kato, Ito et al. 2011, Bhushan, Walesky et 
al. 2014, Bhushan, Poudel et al. 2017). Thus, stimulating liver regeneration in patients 
of APAP-induced ALF holds great therapeutic potential. However, development of novel 
regenerative therapies for ALF is hampered because the mechanisms of liver 
regeneration after APAP-induced ALF are less understood. The long-term goal of Apte 
laboratory is to develop regenerative therapies based on improved liver regeneration for 
APAP-induced ALF. APAP mediated liver injury involves generation of ROS, release of 
endonucleases, severe DNA fragmentation leading to necrosis in centrilobular region 
(McGill, Sharpe et al. 2012). In response to injury, healthy hepatocytes surrounding the 
necrotic zone undergo rapid cell proliferation and liver regenerates the injured mass 





et al. 2014).  Hence, rapidly dividing hepatocytes surrounding the necrotic zone may 
have high propensity for DNA insult (Saintigny, Delacote et al. 2001). This DNA insult 
may trigger the DDR to repair the damage and allow cell cycle progression making it a 
critical step in deciding whether regeneration will be ‘timely’ or ‘delayed’. Hence, the 
objective of this dissertation work was to investigate role of DDR in liver regeneration 
and identify targets with therapeutic potential.  
We used an incremental dose model consisting of a regenerative low dose and 
non-regenerative high dose of APAP to delineate the mechanisms that inhibit liver 
regeneration following APAP-induced ALF. Our hypothesis was that DDR should be 
impaired and checkpoint activation should be prolonged at high dose APAP relative to 
low dose APAP. Thus, differential regulation of DNA damage repair pathways and 
checkpoint activation mediated by p53 after APAP-induced toxicity could be analyzed 
and potential targets to stimulate regeneration after APAP overdose could be identified. 
Further, p53 regulates several cellular processes including DDR. Hence, we 
hypothesized that p53 plays critical role in pathophysiology of APAP toxicity such that it 



















CHAPTER II: INVESTIGATING ROLE OF DNA DAMAGE RESPONSE 
















Acetaminophen (APAP) overdose is a leading cause of acute liver failure (ALF) 
with limited treatment options. Previous studies have shown that liver regeneration 
following APAP induced ALF is a deciding factor in patient outcome. A recent study 
from our laboratory using an incremental dose model involving a regenerating (300 
mg/kg, APAP300) and a non-regenerating (600 mg/kg, APAP600) dose of APAP in 
mice have revealed several pro- regenerative pathways that can improved survival after 
APAP overdose. Here we report the role of DNA damage and repair mechanisms in 
inhibition of liver regeneration in the non-regenerating dose of APAP. Liver injury, 
regeneration and microarray-based global gene expression changes were studied in 
male C57BL6 mice over time course of 0 to 96 hours following treatment with either 
APAP300 or APAP600. The ingenuity pathway analysis of microarray data revealed 
significant differences in DNA damage, replication and checkpoint related pathways in 
regenerating and non-regenerating doses of APAP. Phosphorylation of histone H2AX 
(pH2AX), a marker of the DNA double strand break (DSB), was significantly prolonged 
in mice treated with APAP600 than APAP300. In APAP300 treated mice H2AX was 
rapidly dephosphorylated at Tyr 142, an indication of beginning of the DNA repair 
process. However, HA2X phosphorylation was sustained in APAP600 for the entire 
timecourse. Expression of several DNA repair proteins was substantially lower in 
APAP600. Poly (ADP) ribose polymerase (PARP) activation, involved in DNA repair, 
was significantly higher in APAP300 treated mice as compared to APAP600 treated 





in APAP600 as demonstrated by substantially higher expression of its target genes. 
Taken together, these data illustrate that DNA damage occurs in high dose APAP 
toxicity and lack of prompt DSB repair after APAP overdose leads to prolonged growth 







Acetaminophen (APAP) is widely used analgesic and antipyretic drug present in 
several over the counter and prescription medications. It is safe at therapeutic doses of 
≤ 4 gm per day. However; overdose of APAP can cause acute liver injury (ALI) and 
even acute liver failure (ALF).(Shiffman, Rohay et al. 2015) Overdose of APAP is the 
cause of almost 50% of ALF cases in the US with close to 35% mortality (Ostapowicz, 
Fontana et al. 2002, Larson, Polson et al. 2005). Despite being the major cause of ALF 
in Western world, therapeutic options for APAP induced ALF are extremely limited. 
Several studies in patients and rodents have demonstrated that stimulation of liver 
regeneration improves survival and prognosis after APAP overdose(James, Lamps et 
al. 2003, Schmidt and Dalhoff 2005, Hu and Colletti 2008, Apte, Singh et al. 2009, 
Donahower, McCullough et al. 2010, Bhushan, Walesky et al. 2014). Although these 
studies implicate enhanced liver regeneration in the APAP-induced ALF patients as a 
plausible therapeutic option, the mechanisms are not entirely known. Especially, the 
role of DNA damage response (DDR) in regulation of liver regeneration after APAP 
induced ALI has not been investigated.  
DDR involves proteins that sense DNA damage and trigger a repair response to 
protect the cell. Sensor proteins in DDR detect the damage and send the signal to 
mediator and effector proteins via activation of apical kinases. Mediator proteins recruit 
DNA repair effector proteins at the damaged DNA site, which then carry out the repair 
process(Zhou and Elledge 2000, Sulli, Di Micco et al. 2012). One of the major effector 





till damage is repaired. However, if damage is beyond repair it can activate the cell 
death pathway(Carvajal and Manfredi 2013). Previous studies have shown that APAP 
injury results in nuclear DNA fragmentation preventing the cell proliferation by inducing 
cell cycle arrest(Ray, Sorge et al. 1990, Shen, Kamendulis et al. 1992, Bhushan, 
Walesky et al. 2014). 
We investigated the role of DDR in liver regeneration after APAP toxicity using an 
incremental dose model that includes a regenerating (300 mg/kg, APAP300) and a non-
regenerating (600 mg/kg, APAP600) dose in mice(Bhushan, Walesky et al. 2014). Our 
studies indicated that APAP overdose results in dose dependent DNA damage but at 
higher doses the DNA repair mechanisms fail resulting in initiation of cellular 
senescence and inhibition of liver regeneration. These studies have revealed novel 







2.3 MATERIALS AND METHODS 
Animals, Treatment and Tissue Harvesting.  
All animal experiments were performed in compliance with protocols approved by 
the Institutional Animal Care and Use Committee at University of Kansas Medical 
Center. The details of incremental dose model have been previously 
published(Bhushan, Walesky et al. 2014).  Briefly, male C57BL/6 mice were fasted 
overnight and injected with either 300 or 600 mg/kg APAP intraperitoneally (i.p. 
dissolved in warm saline). Mice (n = 5 to 7) were sacrificed at 0, 3, 6, 12, 24, 48, 72 and 
96 hours after APAP treatment and blood and livers were collected. Parts of liver tissue 
were processed separately to obtain paraffin sections, frozen sections, RNA samples, 
nuclear, cytoplasmic and RIPA total protein extracts as described previously(Wolfe, 
Thomas et al. 2011). Liver injury was assessed by serum alanine aminotransferase 




The following antibodies were used for analyses: (#4588) KU70, (#9532) PARP, 
(#9718) p-H2AX Ser139, (#2524) p53, (#9284) p-p53 S15 from Cell Signaling 
Technologies (Danvers, MA), (SC9051) DNAPkc, (SC1485) KU80, (SC166488) XLF, 
(SC8285) XRCC4, (SC28232) DNA Lig4, (SC642) BRCA1 from Santacruz Biotech. 





00) HNF4α from Perseus proteomics, (nb100-904) 53BP1 from Novus Biolabs and 
(#1020) PAR from Tulips Biolabs. All Alexa fluor secondary antibodies were purchased 
from Invitrogen, Thermo Fisher and HRP conjugated secondary antibodies were 
purchased from Cell Signaling Technologies (Danvers, MA). 
 
Western Blotting.  
Protein estimation of RIPA and nuclear extracts was done by BCA method and 
Western blot analysis was performed using pooled protein extracts as described 
before(Wolfe, Thomas et al. 2011).  
 
Immunofluorescence staining. 
Fresh-frozen liver sections (5 µm thick) were used to detect pH2AX Ser 139 
immunofluorescence as described before(Walesky, Gunewardena et al. 2013). 
 
Real Time PCR. 
Total RNA was isolated from APAP300 and APAP600 livers using Trizol method 
according to the manufacturer’s protocol (Sigma, St. Louis, MO) and converted to cDNA 
as previously described (Apte, Singh et al. 2009). Gene expression of various genes 
was determined by comparing mRNA levels from APAP treated groups at different time 





was used for Real time PCR analysis on the Applied Biosystems Prism 7300 Real-time 
PCR Instrument according to manufacturer’s protocol. 18s gene expression in the same 
samples was used for data normalization. Primers used for real time PCR are listed in 
Table 2.3.1. 
 
Table 2.3.1. Primers used in this study 
Gene Forward (5'-3') Reverse (5'-3') 
GADD45α CCGAAAGGATGGACACGGTG TTATCGGGGTCTACGTTGAGC 
GADD45β CAACGCGGTTCAGAAGATGC GGTCCACATTCATCAGTTTGGC 
GADD45γ GGGAAAGCACTGCACGAACT AGCACGCAAAAGGTCACATTG 
BIRC5 AAGGAATTGGAAGGCTGGG TTCTTGACAGTGAGGAAGGC 
BTG2 ATGAGCCACGGGAAGAGAAC GCCCTACTGAAAACCTTGAGTC 




Gene array experiments were conducted on pooled liver samples (n=3 per 





Pathway Analysis (IPA) of gene array data was conducted as described before 
(Walesky, Gunewardena et al. 2013). 
 
Statistical Analysis. 
Data are shown as mean ± SEM. Student’s T-test was used for statistical 
analysis. Difference between groups was considered statistically significant at P<0.05 







Sustained liver injury and inhibited liver regeneration following higher dose of 
APAP 
Liver injury after APAP300 and APAP600 treatment was assessed using serum 
ALT and histopathological analysis of liver tissue over 0 to 96 hours time 
course(Bhushan, Walesky et al. 2014). At both doses, serum ALT activity was 
increased and peaked at 12 hours after treatment. In APAP300 treated mice, serum 
ALT activity regressed after 24 hours and returned to normal by 72 and 96 hours. 
However, in APAP600 treated mice ALT activity remained high up to 24 hours and later 
decreased but was persistently higher until 96 hours after APAP treatment as compared 
to APAP300 (Fig. 2.4.1A). All mice receiving APAP300 dose recovered from injury, 
whereas mice with APAP600 treatment showed 25% lethality and remaining mice had 
sustained injury up to 96 hours(Bhushan, Walesky et al. 2014). 
To determine the difference in liver regeneration after two doses of APAP, we 
determined expression of PCNA in mouse liver(Bhushan, Walesky et al. 2014). Western 
blot analysis of PCNA revealed significantly delayed and reduced cell proliferation after 
APAP600 dose as compared to APAP300 dose (Fig. 1B and 1C). In APAP300 group, 
significant increase in PCNA was observed from 24 hours upto 72 hours. However, in 
APAP600 group, PCNA expression was delayed untill 48 hours and it was significantly 









Figure 2.4.1. Sustained liver injury and inhibited liver regeneration following 
higher dose of APAP. (A) Liver injury analysis by serum ALT levels after APAP 
treatment. Shown as fold increase in ALT levels compare to 0 hour. (B) Western blot 
analysis of PCNA in whole liver extract. (C) Densitometric analysis of PCNA Western 







IPA Analysis Reveals Differences In DNA Damage And Repair Pathways Between 
APAP 300 And APAP 600 
We performed global microarray analysis to delineate mechanisms that inhibit 
liver regeneration in APAP600 group vs APAP300.  Microarray data obtained were 
analyzed using web-based application Ingenuity Pathway Analysis (IPA). Canonical 
pathway analysis revealed significant differences in several pathways related to cell 
cycle checkpoint and DNA damage signaling as shown in Fig 2.4.2 A-B. In the 
microarray data, many genes that were altered after APAP when compared to 0 hour 
control were common in APAP300 and APAP600 group. Hence, we compared genes 
that were uniquely altered (up or down regulated) in APAP300 or APAP600 relative to 0 
hour. As shown in Fig. 2.4.2 C canonical pathway analysis using unique genes showed 
that DNA damage, repair and replication pathways were significantly altered in 

















Figure 2.4.2. IPA analysis of microaaray data obtained from APAP 300 and APAP 
600 pooled liver samples obtained at 0, 3, 24, 48 hours after APAP treatment. 
Gene expression changes 3 fold and higher were selected for IPA analysis. (A) 
Canonical Pathway analysis of APAP 300, (B) Canonical Pathway analysis of APAP 
600, (C) Canonical Pathway analysis of APAP 300 and APAP 600 at 48 hours based on 





Prolonged DNA DSB and reduced repair protein expression after higher dose of 
APAP  
The microarray data indicated that DNA damage, repair and replication pathways 
were significantly different between dosage groups. Moreover, DNA damage could 
result from replication stress. Therefore, to examine the mechanism underlying delayed 
and attenuated cell proliferation in mice exposed to a higher APAP dose regarding DNA 
replication, we considered the most lethal form of DNA damage i.e. DNA double strand 
break (DSB). DSB was determined using Western blot analysis and 
immunofluorescence detection of Ser 139 phosphorylation of histone 2A.X (pH2AX), a 
hallmark of DSB. At both APAP300 and APAP600 doses, Ser 139 pH2AX expression 
was observed from 6 hours (Fig. 2.4.3 A). In APAP300 group pH2AX-Ser139 
expression peaked at 12 hours, remained high at 24 hours and returned to control level 
at 48 and 72 hours. In APAP600 group pH2AX Ser 139 induction peaked at 12 hours 
and remained high up to 72 hours. To determine which cells exhibit pH2AX after APAP 
overdose, we performed double immunofluorescence staining with pH2AX and 
hepatocyte marker HNF4a. Immunofluorescence staining revealed that hepatocytes 
immediately surrounding APAP induced necrotic zone were positive for DSB (Fig. 2.4.3 
B).  
Next we looked at DNA DSB repair proteins including another modification of 
H2AX i.e. de-phosphorylation at Tyr 142 that facilitates recruitment of repair 
proteins(Cook, Ju et al. 2009, Xiao, Li et al. 2009). Western blot analysis of nuclear 





indicating initiation of DNA repair. In contrast, APAP600 group mice had higher levels of 
pH2AX Tyr142 throughout the time course (Fig. 2.4.3 A). BRCA1 and 53BP1 are critical 
mediator proteins involved in DDR, which can interact with broken DNA ends and help 
binding of DNA repair effector proteins at the damaged DNA site(Jackson 2002, Panier 
and Boulton 2014). A marked increase in 53BP1 and BRCA1 protein levels was seen 
from 12 hours up to 72 hours after APAP300 treatment as compared to 0 hour control. 
In contrast, 53BP1 and BRCA1 protein expression was down regulated after APAP600 
treatment (Fig. 2.4.3 C).  
We have previously demonstrated that in APAP600 group hepatocytes were 
arrested at G0/G1 phase(Bhushan, Walesky et al. 2014). In G0/G1 phase of the cell 
cycle, DSB is repaired mainly by non-homologous end joining (NHEJ)(Chapman, Taylor 
et al. 2012). Therefore, we studied NHEJ repair pathway proteins to further examine the 
difference in DNA repair between APAP300 and APAP600 groups. We determined 
expression of proteins involved in NHEJ repair including KU70, KU80, DNA Pkc, 
XRCC4, XLF, and DNA Lig4 using Western blot analysis (Fig. 2.4.3 D). The data 
indicated significant upregulation of XRCC4, XLF, DNA Pkc and Lig4 in APAP300, all of 
which were downregulated in APAP600 group as compared to the 0 hour control (Fig. 
2.4.3 D). We did not observe differences in KU70 and KU80 protein levels between 
APAP300 and APAP600 groups.  
These data suggest that after higher dose of APAP there is reduced DNA repair 












Figure 2.4.3. Prolonged DNA DSB and reduced repair protein expression after 
higher dose of APAP. A) Immunoblot analysis of phos-H2AX Ser 139 using total liver 
extract and phos-H2AX Tyr 142 using nuclear extract. (B) Representative 
immunofluorescence staining for pH2AX Ser139 (green), HNF4α (red) and DAPI (blue) 
for cell nuclei. Arrowheads are pointing to necrotic cells. (C) Immunoblot analysis of 
DNA repair mediator proteins 53BP1, BRCA1in total liver extract (D) Immunoblot 
analysis of DNA repair effector proteins KU70, KU80, DNAPkc, XRCC4, XLF, Lig4 





Reduced PARP activation following APAP600 dose of APAP  
Another critical protein in DDR is poly (ADP) ribose polymerase (PARP-1) that 
senses DNA damage and mediates the stress response by poly-ADPribosylation of 
nuclear proteins. It results in chromatin remodeling, which favors DNA 
repair(Krishnakumar and Kraus 2010). We did not observe differences in total PARP1 
protein expression between APAP300 and APAP600 mice. However, nuclear PARP1 
(N-PARP1) was significantly downregulated in APAP600 treated mice as compare to 
APAP300 treatment (Fig. 2.4.4 A). Next, we determined PARP activation by staining for 
PARylated proteins using immunohistochemistry (Fig. 2.4.4 B). Following APAP300 
dose, PARP activation was observed in a time-dependent manner. No PAR staining 
was evident untill 12 hours (data not shown), but significant nuclear PAR staining was 
evident from 12 to 72 hours after APAP300 treatment. PAR staining intensity 
significantly increased at 24 hours, sustained till 72 hours and disappeared by 96 hours 
after APAP300 treatment. On the contrary, in APAP600 treated mice, at 12 and 24 
hours very few cells stained positive for PAR with low intensity. At 48 hours many PAR 
positive cells were observed however staining intensity was weak as compare to 
APAP300. PAR staining disappeared by 72 hours following APAP600 treatment. These 
data indicate that PARP activation is significantly higher and sustained following 






Figure 2.4.4. Delayed activation of PARP following APAP600 treatment. (A) 
Immunoblot analysis of PARP1 in total liver extract and nuclear extract. (B) 









Increased transcriptional activation of p53 at APAP600 exposure 
p53 is the major effector protein of DDR pathway, which can activate cell cycle 
checkpoint and arrest the cell cycle till damage is repaired. Stabilization and activation 
of p53 protein has been shown to play an important role in many cellular processes 
such as cell cycle arrest, cell senescence, cell death, cell metabolism etc(Riley, Sontag 
et al. 2008, Vousden and Prives 2009). We determined p53 activation using Western 
blotting for p53 and mRNA for several p53 target genes after APAP overdose. Western 
blot analysis of APAP300 and APAP600 samples indicated marked increase in p53 
stabilization after APAP treatment (Fig. 2.4.5 A). Interestingly, p53 protein levels were 
significantly higher in APAP600 group as compare to APAP300 from 6 hours up to 72 
hours. Similarly, Ser 15 phosphorylation of p53, which indicates activation of p53, was 
significantly higher in APAP600 at all time points (Fig. 2.4.5 A). Real time PCR analysis 
showed that expression of several p53 responsive genes involved in cell cycle inhibition 
(GADD45α, GADD45β, GADD45γ, BTG2) (Fig. 2.4.5 B), cell senescence (PAI1) (Fig. 
2.4.5 C) and cell death (repression target - BIRC5) (Fig. 2.4.5 D) corroborated with 
increased p53 activity. A marked increase in all cell cycle inhibitor and cell senescence 
gene expression was seen in both groups after APAP treatment. In APAP300 group, 
mRNA levels of all these genes were significantly reduced from 24 hours to 96 hours. 
However, these cell cycle inhibitor and senescence gene expressions was sustained 
and significantly higher in APAP600 group. BIRC5, gene associated with inhibition of 
cell death and negatively regulated by p53, was significantly up regulated in APAP300 
group at later time points, in contrast it remained repressed throughout the time course 













Figure 2.4.5. Activation of p53 is higher following APAP600 treatment. (A) Western 
blot analysis of p53 and phospho-p53 Ser15 using total liver extract. Real time PCR 
analysis of p53 target genes regulating (B) cell cycle inhibition Gadd45α, Gadd45β, 
Gadd45γ, BTG2 (C) replicative senescence PAI1 and (D) cell death inhibition BIRC5 * 






APAP is a safe analgesic and antipyretic drug when taken at recommended daily 
dose. It is safely metabolized in liver and excreted in urine. However, overdose of APAP 
causes ALI and even ALF, which is a number one cause of ALF in USA and 
UK.(Larson, Polson et al. 2005, Bernal and Wendon 2013) The mechanism of APAP 
toxicity involves generation of ROS, release of endonucleases, extensive DNA 
fragmentation and subsequent cell necrosis(Jaeschke and Bajt 2006). In response to 
injury, healthy hepatocytes surrounding the necrotic zone divide rapidly and help repair 
the injured liver(Bajt, Knight et al. 2003, Apte, Singh et al. 2009, Bhushan, Walesky et 
al. 2014). In previous study we have demonstrated that liver regeneration is stimulated 
rapidly following treatment with 300 mg/kg of APAP (regenerating dose) but it is 
significantly delayed and blunted after a 600 mg/kg of APAP (non-regenerating 
dose)(Bhushan, Walesky et al. 2014). The main reason behind this is the cells that 
surround the necrotic zone, which normally undergo proliferation to fuel liver 
regeneration are arrested in mice treated with the higher non-regenerating dose of 
APAP.  In this study, we determined if this cell cycle arrest at non-regenerating doses is 
due to enhanced DNA damage and blunted DNA repair processes. Our data indicate 
that DNA damage occurs following both the regenerating (APAP300) and non-
regenerating (APAP600) doses of APAP but DNA repair process is significantly 
inhibited following treatment with non-regenerating dose of APAP. Furthermore, our 
immunofluorescence data demonstrated that the extensive DNA damage observed at 





the hepatocytes that are required to proliferate in order to ensue liver regeneration. 
Whereas previous studies have shown that DNA damage is part of necrotic cell death 
after APAP, our data are the first to demonstrate that DNA damage and subsequent 
lower DNA repair inhibit liver regeneration, repair and recovery after APAP overdose. 
Because we observed sustained DSB in non-regenerating animals, we further 
studied whether DSB repair is inactive and cells are arrested due to failure to replicate 
damaged DNA in APAP600.  De-phosphorylation of p-H2AX at Tyr 142 is one of the 
chromatin modifications that facilitate DSB repair(Cook, Ju et al. 2009, Xiao, Li et al. 
2009) was significantly deregulated following treatment with the non-regenerating 
APAP600 dose.  Additionally, higher dose of APAP suppressed expression of mediator 
proteins 53BP1 and BRCA1 (Fig. 2C). Expression of several DSB repair effector 
proteins was suppressed at non-regenerating doses. Because DSB repair is the 
collective effort of various proteins, lack of several critical proteins will result in delayed 
or completely suppressed DAB repair in APAP600 treated mice. Furthermore, 
dephosphorylation of H2AX at Tyr 142, which is required for easy access of repair 
proteins to DSB sites was significantly lower in APAP600 treated mice. This may have 
made damage site inaccessible for the repair protein in non-regenerating dose treated 
mice. These results collectively show that DSB repair is deregulated in non-
regenerating animals leading to sustain DSB.  
Further studies showed that APAP600 treated mice exhibited reduced nuclear 
PARP1 levels in spite of similar amounts of total PARP1 levels as compared to 





in protein PARylation(Schreiber, Dantzer et al. 2006, Gibson and Kraus 2012). Our data 
indicate that 6 hours following APAP600, PARP1 is rapidly removed from the nucleus. 
This was consistent with significantly decreased PARylation of nuclear proteins in 
APAP600. In agreement with previous study(Cover, Fickert et al. 2005), these data 
show that PARP activation is not associated with increased liver injury following APAP 
toxicity. However, these data suggest that PARP activation is a critical step in DSB 
repair following APAP overdose. Further studies are required to delineate the 
mechanism of nuclear export of PARP1 following higher dose of APAP. 
p53 is a primary effector protein that plays a critical role in cell cycle regulation 
during DDR. Under stress conditions p53 is stabilized and activated through various 
posttranslational modifications. One such modification is phosphorylation at Ser 15 that 
leads to transcriptional activation of p53. Activated p53 regulates plethora of 
downstream gene expression involved in cell cycle inhibition and senescence(Riley, 
Sontag et al. 2008).  Our data indicate significantly higher and sustained activation of 
p53 following APAP600 dose (Fig. 4A).  The expression of p53 target genes (Cell cycle 
inhibitor- GADD45α, GADD45β, GADD45γ, cell senescence PAI1, p21) increased after 
both APAP300 and APAP600 but it was significantly higher in APAP600 dose at all time 
points. Previous studies indicate that moderate activation of p53 results in cell cycle 
arrest that permit cell to repair the DNA damage, however excessive and sustained 
activation of p53 results in replicative senescence and cell death(Vousden and Prives 
2009). Further, BIRC5, a negative target of p53 was repressed at all time points in non-
regenerative dose consistent with higher p53 activation. These data suggest that 





whereas, sustained excessive activation of p53 at non-regenerative dose may cause 
prolonged growth arrest, replicative senescence or cell death. Further studies are 
required to demonstrate the exact role of p53 and some of these target genes in liver 
regeneration after APAP overdose. 
In conclusion, our study indicates that DNA damage and repair response plays a 
critical role in deciding whether liver regeneration will be ‘timely’ or ‘delayed’ following 
APAP overdose. At high doses of APAP, DSB repair is impaired resulting in inhibited 
liver regeneration. This study is the first to highlights the complex signaling pathway 
involved in DNA DSB repair in regulation of liver regeneration following APAP induced 
ALI. These data also indicate that improving DNA repair may have therapeutic benefit 



























CHAPTER III: INVESTIGATING PLEIOTROPIC ROLE OF P53 IN LIVER 

















p53 is the major cellular gatekeeper, which regulates diverse functions including 
proliferation, cell death, cell migration, metabolic homeostasis. The role of p53 in 
pathogenesis of drug-induced liver injury is poorly defined. We investigated the role of 
p53 in liver injury and regeneration after APAP overdose, the most common cause of 
acute liver failure in the Western world. Eight-week-old male WT and p53KO mice 
(C57BL/6J background) were treated with 300mg/kg APAP (APAP300) and the 
dynamics of liver injury and regeneration were studied over time course of 0 to 96 hour. 
Deletion of p53 resulted in a 3-fold higher liver injury than WT mice implying protective 
role for p53 in injury progression. Interestingly, despite higher liver injury p53KO mice 
recovered similarly as the WT mice due to faster liver regeneration. Deletion of p53 did 
not affect APAP bioactivation however it delayed clearance of APAP protein adducts 
from liver. Global Transcriptomic analysis revealed that p53KO mice had disrupted 
metabolic homeostasis, induced inflammatory and proliferative signaling. p53KO mice 
showed prolonged steatosis, hypoglycemia, impaired GSH transulfuration and reduced 
expression of mitochondrial complex proteins correlating with prolonged liver injury. 
Deletion of p53 also resulted in increased expression of cytokines such as IL1β and 
IL10 in liver. Further, p53KO mice displayed delayed but rapid liver regeneration than 
WT mice due to sustained AKT, ERK and mTOR signaling. These studies show that 
p53 plays a pleotropic role after APAP overdose where it prevents progression of liver 
injury by maintaining mitochondrial and metabolic homeostasis and also regulates 






p53 functions as a cellular gatekeeper involved in regulation of various stress 
responses including cell proliferation, migration, metabolism, autophagy, DNA repair, 
senescence, immune response and stem cell reprogramming. Because of these 
multifaceted functions, deregulation of p53 is implicated in various diseases such as 
cancer, obesity, diabetes, ischemia, and aging (Tyner, Venkatachalam et al. 2002, 
Muller, Vousden et al. 2011, Kenzelmann Broz and Attardi 2013, Menendez, Shatz et 
al. 2013, Aloni-Grinstein, Shetzer et al. 2014, Kruiswijk, Labuschagne et al. 2015). 
Recent studies in rodents using partial hepatectomy model have depicted role of p53 in 
regulation of ploidy and cell proliferation during liver regeneration (Stepniak, Ricci et al. 
2006, Kurinna, Stratton et al. 2010, Kurinna, Stratton et al. 2013, Jin, Hong et al. 2015, 
Zhang, Liu et al. 2015). Liver regeneration is essential for patient survival following 
surgical resection or acute and chronic liver injury secondary to drugs, toxins and 
viruses (Mehendale 2005). However, role of p53 in liver homeostasis and regeneration 
following drug induced liver injury is not known. 
Overdose of acetaminophen (APAP), the commonly used antipyretic and 
analgesic agent, is the leading cause of Acute Liver Failure (ALF) in the Western world 
(Larson, Polson et al. 2005, Bernal and Wendon 2013, Shehab, Lovegrove et al. 2016). 
The mechanism of liver injury after APAP overdose involves formation of a reactive 
metabolite N-acetyl-p-quinoneimine (NAPQI), which depletes cellular glutathione and 
covalently binds to protein. These initial events lead to oxidative stress, activation of c-





Apoptosis inducing factor (AIF) and endonuclease that cause nuclear DNA 
fragmentation and eventually hepatocyte necrosis (Jaeschke and Bajt 2006). The 
replacement of necrotic cells and restoration of liver function occurs through liver 
regeneration. Several studies have shown that enhanced liver regeneration following 
APAP induced liver injury improves final outcome (Schmidt and Dalhoff 2005, Bhushan, 
Walesky et al. 2014).  
Whereas recent studies have implicated p53 in pathogenesis of APAP induced 
liver injury, the exact role of p53 in initiation and progression of injury and the 
subsequent liver regeneration after APAP overdose is not clear (Stamper, Garcia et al. 
2015, Huo, Yin et al. 2017). In this study, we investigated role of p53 in liver injury and 
regeneration using APAP overdose in WT and p53 KO mice. Our findings reveal that 
p53 regulates metabolic homeostasis, inflammatory response and initiation of cell 
proliferation and disruption of p53 signaling culminates in progression of liver injury yet 






3.3 MATERIALS AND METHODS 
Animals, Treatments and Tissue Harvesting.  
Two-month-old male WT (p53+/+) and p53KO (p53-/-) mice on C57BL/6J 
background purchased from Jackson Laboratories were used in these studies. All mice 
were housed in Association for Assessment and Accreditation of Laboratory Animal 
Care-accredited facilities at the University of Kansas Medical Center under a standard 
12hour light/dark cycle with access to chow and water ad libitum. All animal 
experiments were performed with approved Institutional Animal Care and Use 
Committee protocols at University of Kansas Medical Center. Acute liver injury was 
induced by injecting 300 mg/kg APAP intraperitoneally (i.p. dissolved in saline) following 
12hour fasting as described previously (Bhushan, Walesky et al. 2014). Following APAP 
treatment mice (n = 3 to 5) were sacrificed at 0, 1, 12, 24, 48 and 96 hours and blood 
and livers were collected. Serum samples obtained from blood were used for ALT and 
glucose level measurement using the Infinity ALT (GPT) and the Infinity Glucose kit 
(Thermo Scientific; Middletown, VA) as per the manufacturer’s protocol. Parts of liver 
tissue were processed separately to obtain paraffin sections, frozen sections, RNA 
samples, nuclear, cytoplasmic and RIPA total protein extracts as described previously 








Immunohistochemistry and staining procedures. 
Hepatocyte proliferation was determined using PCNA immunohistochemical 
staining and liver necrosis was determined by H&E staining as previously described 
(Borude, Edwards et al. 2012).  Fresh-frozen liver sections (5 µm thick) were used to 
stain lipid droplets using Oil Red O as described before (Borude, Edwards et al. 2012). 
 
Western Blotting and Real time PCR.  
Protein estimation and Western blot analysis was performed using pooled protein 
extracts as described before (Borude, Edwards et al. 2012). The antibodies used in this 
study are listed in Supplemental Table 3.3.1. Total RNA isolation from WT and p53KO 
liver, reverse transcription to cDNA and Real time PCR analysis by SYBR Green 
technology was performed as previously described (Bhushan, Walesky et al. 2014). 18s 
gene expression in the same samples was used for data normalization and Messenger 
RNA (mRNA) levels were determined by comparing post APAP treatment time points to 










Table 3.3.1. Antibodies used in this study 
Name Catalog Number 
PCNA Cell Sign-2586 
p-JNK Cell Sign -4668 
JNK Cell Sign -3708 
Cyclin D1 Cell Sign -2978 
p-pRb Cell Sign -9308 
p21 Santa cruz-6246 
GAPDH Cell Sign -2118 
CYP2E1 Abcam- 19140 
SREBP2 Thermo- PA1338 
TFAM Cell Sign -8076 
NRF1 Cell Sign -12381 
Mitochondrial Complex  Mitosci- MS604 
p-AKT Cell Sign -9271 
AKT Cell Sign -4691 
p-ERK Cell Sign -4376 
p-EGFR Cell Sign -1068 
EGFR Cell Sign -4267 
p-mTOR Ser 2448 Cell Sign -2971 
p-mTOR Ser 2481 Cell Sign -2974 





p-P70S6K Cell Sign -9234 
P70S6K Cell Sign -9202 
 
Table 3.3.2. Primers used in this study 
Gene Forward (5'-3') Reverse (5'-3') 
Acot1 ATACCCCCTGTGACTATCCTGA CAAACACTCACTACCCAACTGT 
Cd14 CTCTGTCCTTAAAGCGGCTTAC GTTGCGGAGGTTCAAGATGTT 
Cyp7a1 GGGATTGCTGTGGTAGTGAGC GGTATGGAATCAACCCGTTGTC 
Fasn GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG 
Fdps GGAGGTCCTAGAGTACAATGCC AAGCCTGGAGCAGTTCTACAC 
Fos CGGGTTTCAACGCCGACTA TTGGCACTAGAGACGGACAGA 
Hmox1 AAGCCGAGAATGCTGAGTTCA GCCGTGTAGATATGGTACAAGGA 
Elovl3 TTCTCACGCGGGTTAAAAATGG GAGCAACAGATAGACGACCAC 
Ly6d GCCTGGGCACTTCGATGTC TGAGTTTGCACACTCTTTCC 
Igfbp3 CCAGGAAACATCAGTGAGTCC GGATGGAACTTGGAATCGGTCA 
Acot2 GTTGTGCCAACAGGATTGGAA GCTCAGCGTCGCATTTGTC 
Afp CTTCCCTCATCCTCCTGCTAC ACAAACTGGGTAAAGGTGATGG 
Cd36 GCGCATGATTAATGGCACAG GATCCGAACACAGCGTAGATAG 
Scd1 CTACAAGCCTGGCCTCCTGC  GGACCCCAGGGAAACCAGGA  
Pdk4 AGGGAGGTCGAGCTGTTCTC GGAGTGTTCACTAAGCGGTCA 
Stat1 TCACAGTGGTTCGAGCTTCAG GCAAACGAGACATCATAGGCA 





G0s2 TAGTGAAGCTATACGTTCTGGGC GTCTCAACTAGGCCGAGCA 
Fgf21 CTGCTGGGGGTCTACCAAG CTGCGCCTACCACTGTTCC 
Lpin1 CATGCTTCGGAAAGTCCTTCA GGTTATTCTTTGGCGTCAACCT 
Gadd45α CCGAAAGGATGGACACGGTG TTATCGGGGTCTACGTTGAGC 
Gadd45β CAACGCGGTTCAGAAGATGC GGTCCACATTCATCAGTTTGGC 
Gadd45γ GGGAAAGCACTGCACGAACT AGCACGCAAAAGGTCACATTG 
Bax TGAAGACAGGGGCCTTTTTG AATTCGCCGGAGACACTCG 
Birc5 AAGGAATTGGAAGGCTGGG TTCTTGACAGTGAGGAAGGC 
Btg2 ATGAGCCACGGGAAGAGAAC GCCCTACTGAAAACCTTGAGTC 
Cpt1a CTCCGCCTGAGCCATGAAG CACCAGTGATGATGCCATTCT 
Gpx1 AGTCCACCGTGTATGCCTTCT GAGACGCGACATTCTCAATGA 
Gpx3 CCTTTTAAGCAGTATGCAGGCA CAAGCCAAATGGCCCAAGTT 
Nanog TCTTCCTGGTCCCCACAGTTT GCAAGAATAGTTCTCGGGATGAA 
Sco2 AGCTCTCTCAGTTCAAACCCC GCAGTCTAGTTCTTAGCCCAGG 
Sod2 TGCTCTAATCAGGACCCATTG  CATTCTCCCAGTTGATTACATTCC  
Tgfβ AGCTGGTGAAACGGAAGCG  GCGAGCCTTAGTTTGGACAGG  
Il1β GAAATGCCACCTTTTGACAGTG  CTGGATGCTCTCATCAGGACA 









Hepatic GSH and APAP protein adducts measurement.  
Total hepatic GSH levels were measured in liver homogenates using the 
commercially available colorimetric assay kit (Sigma) as described before (Bhushan, 
Borude et al. 2013).  APAP protein adducts were measured in liver and serum samples 
using HPLC method as previously described (McGill, Lebofsky et al. 2013). 
 
Transcriptome and Pathway analysis.  
Total RNA isolated from WT and p53KO livers at 12, 24 and 48hour post APAP 
treatment were used for global transcriptomic analysis. Equal amount of RNA was 
pooled from 3 representative samples at each time point from both groups. RNA 
Integrity was determined on the Agilent Bioanalyzer 2100 using the RNA6000 Nano 
assay kit VII and global transcriptomic analysis was performed using Affymetrix Clariom 
D array at the Genomics Core Facility of the University of Kansas Medical Center 
(Kansas City, KS). Hierarchical clustering and heatmap analyses of differential 
expression data of transcripts were done as described previously (Walesky, Edwards et 
al. 2013). Ingenuity Pathways Analysis (IPA, Ingenuity Systems) was used for functional 








Mitochondrial DNA measurement.  
Genomic and mitochondrial DNA was isolated using commercially available kit 
(Qiagen). Real time PCR analysis was used to quantify relative copy numbers of 
genomic DNA and mitochondrial DNA (mito DNA) in WT and p53KO mice livers from 0-
96 hours time course.  LPL as nuclear DNA target and ND1 as mito DNA target were 
used for mito DNA content measurement. Exponential amplification efficiency of each 
primer pair was confirmed using series of dilution and 5ng of DNA was used in final 
PCR reaction. Mito DNA content in each sample was calculated as described previously 
(Rooney, Ryde et al. 2015). Relative mito DNA fold change was calculated by dividing 
mito DNA value of a sample by average mito DNA value in WT at respective time point. 
 
Statistical Analysis. 
All data are shown as mean ± SEM. Student’s t-test was used for statistical 
analysis. Difference between groups was considered statistically significant at P<0.05 







p53 deletion results in progression of APAP induced injury and faster recovery.  
APAP treatment resulted in significant liver injury in both WT and p53KO as 
demonstrated by histopathological (Fig. 3.4.1A) and serum ALT (Fig. 3.4.1B) analysis. 
Liver sections stained with H&E showed necrotic cell injury at 12 and 24 hours in WT 
animals, which reduced by 48 hours. Serum ALT levels corroborated the 
histopathological findings. Liver injury was similar in WT and p53KO mice till 12 hours. 
However, at 24 hours p53KO mice exhibited significant higher liver injury as 
demonstrated by increase in necrotic area and 3-fold higher serum ALT. Interestingly, 
despite very high liver injury, p53KO mice recovered similarly to WT at 48 hours after 
APAP treatment. JNK activation (phosphorylation) is a critical step in APAP 
pathophysiology. Western blot analysis of p-JNK revealed prolonged JNK activation 
after APAP treatment in p53KO than WT group (Fig. 3.4.1C).    
 
p53 deletion results in delayed but faster liver regeneration.  
WT mice showed moderate increase in cell proliferation by 24 hours 
accompanied by increased expression of cell cycle proteins Cyclin D1, p-pRb, PCNA 
(Fig. 3.4.1C-D). PCNA staining of liver sections also revealed increased cell proliferation 
surrounding necrotic zone by 24 hours in WT group (Fig. 3.4.1D). On the contrary, 





appearance of PCNA positive cells and delayed increase in Cyclin D1 expression till 48 
hours after APAP treatment (Fig. 3.4.1D). At 48 hours post APAP, Cyclin D1, p-pRb and 
PCNA protein levels were comparable to WT (Fig. 3.4.1C).  Interestingly, expression of 
p21, a cell cycle inhibitor, was higher in p53KO group at 24 hours than WT, which 










Figure 3.4.1. Deletion of p53 aggravates APAP induced acute liver injury yet 
promotes faster recovery. WT and p53KO mice were treated with APAP300 dose, 
serum and livers were harvested and processed post treatment for histological and 
biochemical analysis. (A) Representative photomicrographs of H&E stained livers. 
Dotted line shows necrotic area. (B) Serum ALT levels. (C) Western blot analysis of p-
JNK, JNK, Cyclin D1, p-pRb, p21, PCNA using total liver extracts from the respective 
groups. (D) Representative photomicrographs of PCNA stained livers. Arrowheads point 






p53 deletion does not change APAP bio activation but delays APAP-adduct 
clearance from liver.  
Because we observed higher injury in p53KO mice, we measured total hepatic 
GSH, CYP2E1 and APAP adducts (McGill, Lebofsky et al. 2013, Ni, McGill et al. 2016), 
which are involved in initiation of APAP toxicity, to determine whether changes in 
bioactivation of APAP can explain the higher injury. CYP2E1 protein expression was not 
different between two groups (Fig. 3.4.2A). Total GSH levels before APAP treatment 
were similar and depleted GSH to same extent 1 hour after APAP administration in both 
groups. Interestingly, GSH replenishment, known to be involved in injury progression 
was not altered by p53 deletion as well (Fig. 3.4.2B). Also, we did not observe any 
significant difference in APAP adduct formation in liver at 1 hour post APAP300 
treatment in p53KO mice compared to WT mice (Fig. 3.4.2C inset). All these data 
indicate that deletion of p53 in mice does not affect APAP bio activation. However, we 
observed a decrease in adducts clearance in p53KO mice than WT mice (Fig. 3.4.2C). 
WT mice were able to remove 30% of total adducts (formed at 1 hour) from liver by 12 
hours. In contrast, p53KO mice cleared only 17% of adducts at 12 hours post-APAP 
treatment. By 24 hours p53KO were able to remove liver adducts to same extent as WT 
mice. This delay in liver adduct clearance was accompanied by delayed serum adduct 
secretion in p53KO mice (Fig. 3.4.2D). In WT mice maximum (62% of total serum 
adducts secreted from 1 through 24 hours) adduct secretion in serum was observed at 
12 hours, however, in p53KO mice maximum adduct secretion (69%) was delayed up till 








Figure 3.4.2. p53 deletion does not change APAP bioactivation but delays APAP-
adduct clearance from liver. (A) Immunoblot of CYP2E1 using total liver extract from 
untreated WT and p53KO mice (B) Hepatic total GSH levels. (C) Bar graphs showing 
clearance of APAP-Cys adducts in liver, inset shows actual liver adduct levels, (D) bar 
graph showing clearance of APAP-Cys adducts from serum, inset shows actual adduct 







Transcriptomics analysis revealed expression patterns within each group.  
We performed global transcriptomic analysis to delineate mechanisms through 
which p53 regulates progression of liver injury and initiation of regeneration. We did not 
observe any difference in liver injury between WT and p53KO mice till12 hours. 
However, significant difference was observed at 24 hours in injury progression and 
initiation of liver regeneration after APAP treatment. Therefore, we chose three time 
points including 12, 24 and 48 hours for transcriptome analysis. p53KO transcript 
expression was normalized to WT at respective time points. We selected all (3495) 
transcripts with ≥2 fold up or down regulated expression at least at one time point. Next, 
we sorted coding (676) and noncoding (1439) transcripts individually among 3495 
transcripts and performed hierarchical clustering analysis on their differential expression 
data as shown in (Fig. 3.4.3A-C). Dendrograms generated by cluster analysis of all 
selected transcripts (Fig. 3.4.3A), coding transcripts (Fig. 3.4.3B) and noncoding 
transcripts (Fig. 3.4.3C) revealed two clusters of expression pattern. Cluster 1 consists 
of WT 48, p53KO 48 and WT 24, while Cluster 2 consists of WT 12, p53KO 12 and 
p53KO 24. Within Cluster 1, transcript expression pattern of WT 48 and p53KO 48 was 
closely related indicating similarity of both groups at pathophysiological level, which is 
consistent with injury and recovery data. Interestingly, WT 24 transcript expression 
pattern varied slightly but was very similar to WT 48 and p53KO 48. This shows that WT 
group begin to express Cluster 1 pattern at 24 hours and continues till 48 hours after 
APAP treatment. However, deletion of p53 delayed transcript expression pattern from 
24 hours to 48 hours, which is also consistent with observations of liver regeneration. 





indicating similar pathophysiological condition in both groups.  p53KO 24 expression 
pattern is related to WT 12 and p53KO 12 but varied highly in magnitude which is also 
consistent with observations of liver injury. Finally, transcript expression pattern of WT 
24 and p53KO 24 was significantly contrasting in all transcripts (Fig. 3.4.3A), coding 
(Fig. 3.4.3B) and noncoding transcript (Fig.3.4.3C). This is consistent with the three-fold 
difference in liver injury and delayed initiation of liver regeneration observed in p53KO 
mice as compared to WT mice at 24 hours time point. Further, selection of up and down 
regulated transcripts at individual time point with expression ≥2 fold in p53KO than WT 
revealed that majority of transcripts were significantly affected at 24 hours (Fig.3.4.3D). 
These data show that p53KO mice respond similarly to WT mice till 12 and 48 hours 








Figure 3.4.3 Transcriptomic expression patterns in WT and p53KO mice liver post 
APAP300 treatment. Global transcriptome analysis was performed using Affymetrix 
Clariom D array. Bi-weight (log2) values were used for cluster analysis and presented 
as heatmaps of (A) All selected transcripts (B) only coding transcripts (C) only non 
coding transcripts. Every group title represents the genotype and the time point post 
APAP300 treatment. (D) Number of transcripts in p53KO at respective time point with 






Functional analysis of transcriptomic data revealed changes in metabolic 
homeostasis, inflammation and proliferation. 
The transcript expression data were further analyzed using Core Analysis in IPA 
(Ingenuity Pathway Analysis) followed by comparison analysis between three time 
points. This analysis revealed differentially regulated upstream regulators, biofunctions 
and canonical pathways (Fig. 3.4.4A-C, Table 3.4.1). This analysis revealed that 
transcript expression changes can be categorized into three groups: disrupted 
metabolic homeostasis (upstream regulators- ACOX1, PPARa, SREBP2), increased 
inflammatory signaling (upstream regulators- IL1β, TNFa, IL1A, NF-kB complex and 
TLRs) and proliferative signaling (upstream regulators- CREB1, ERK, TNFa, NUPR1). 
Next, we validated transcriptomic gene expression data of selected genes chosen from 

















Figure 3.4.4. Functional analysis on transcriptomic data using IPA. Comparison 
analysis in the form of heatmap of top (A) Upstream regulators (B) Diseases and bio 
functions (C) Canonical Pathways, post APAP300 treatment in p53KO mice vs WT 
mice. (D) Validation of transcriptomic data by Real Time PCR analysis of representative 
genes. (E) Individual graphs of gene expression fold change values determined by Real 
Time PCR. Gene expression in p53KO mice relative to WT mice at respective 










12hour 24hour 48hour 
ACOX1 -1.05 -6.2 -2.2 
NUPR1 1.4 6.5 -1.3 
PPARa 2.8 4.2 1.6 
IL1b 0.7 5.8 2.1 
CREB1 2.3 5 0.4 
PDGF BB 1.3 4.6 -1.5 
SCAP 0 -4.5 -2.8 
TNF 1.5 4.8 -0.8 
XBP1 1.2 -5.7 0 
POR 0.8 4.1 2 
F2 1.7 5 0 
SREBF2 0.4 -4.2 -2 
HNF1A -0.9 -4 -1.2 
ERK 0.3 5 0 
IL2 0.1 4.3 -0.8 
SFTPA1 -1.1 -4 0 
IL1A 0.2 3.7 -1.1 





MYD88 0.6 3.9 0.2 
IFNG 0.6 3.7 -0.3 
MEK 1 3.6 0 
NFkB (Complex) -0.1 3.6 -0.7 
TLR3 0.6 3.8 0 
TLR4 -0.2 4 0 
TICAM1 0 4 0 







Deletion of p53 induced prolonged steatosis and hypoglycemia following 
APAP300 treatment in mice. 
The transcriptomic data indicated that p53KO mice had changes in metabolic 
homeostasis after APAP administration. Therefore, we analyzed hepatic lipid content 
and serum glucose levels. Oil Red O staining of liver sections revealed that APAP 
treatment induced steatosis at 1 hour and 12 hours and it was resolved by 24 hours in 
WT mice (Fig. 3.4.5A).  p53KO mice liver showed slightly higher steatosis at 0 hour than 
WT, which further increased after APAP treatment, remained significantly higher than 
WT mice till 24 hours and disappeared at 48 hours. Steatosis resolution was delayed by 
24 hours in p53KO mice as compared to WT (Fig. 3.4.5A).  SREBP2 is the major lipid 
sensor in the hepatocytes. The prolonged steatosis in p53KO mice was accompanied 
by prolonged SREBP2 expression and cleavage (Fig. 3.4.5B). Further, p53KO mice 
exhibited more decrease in serum glucose levels post APAP300 treatment as compared 








Figure 3.4.5. Prolonged steatosis and hypoglycemia in p53KO mice liver post 
APAP300 treatment. (A) Representative photomicrographs of Oil Red O-stained frozen 
liver sections from WT and p53KO mice (B) Western blot analysis of SREBP2 and 









Deletion of p53 reduced expression of mitochondrial complexes and induces 
ROS. 
Mitochondria are central to APAP-induced injury (McGill, Sharpe et al. 2012). 
Studies have shown role of p53 in mitochondrial biogenesis and function (Park, Wang et 
al. 2009). To investigate effect of p53 deletion post APAP treatment on number of 
mitochondria we measured mitochondrial DNA content in mice liver. p53KO mice tend 
to have reduced mitochondrial copy number than WT till 24 hours, but at 24 hours a 
marked increase in mitochondrial copy number was observed (Fig. 3.4.6A).  Further, 
Western blot analysis of mitochondrial complexes revealed that p53KO mice exhibited 
significantly low expression of complex I, II, and V up to 24 hours than WT mice (Fig. 
3.4.6B and C).  TFAM and NRF1 are the two transcription factors that regulate 
expression of mitochondrial complexes (Kelly and Scarpulla 2004). Protein expression 
of NRF1 was not significantly different between two groups however; TFAM levels were 
low initially during the first 12 hours after APAP treatment but were induced at 24 hours 
after APAP treatment in p53KO than WT correlating with induction of complex I, II, and 
V at 24 hours (Fig. 3.4.6B and C).  
We further studied if p53KO mice have increased oxidative stress at 24 hours by 
measuring hepatic total GSH level. Indeed, hepatic GSH level was decreased in p53KO 
mice at 24 hours than WT mice (Fig. 3.4.6D upper panel). Low GSH levels can result 
from increased ROS and reduced GSH synthesis. One of the target genes of p53 is an 
enzyme called guanidinoacetate methyltransferase (GAMT), which is involved in GSH 





expression, which were highly up regulated at 24 hours after APAP treatment in the WT 
mice. Interestingly, p53KO mice had reduced expression of GAMT throughout the time 
course than WT and at 24hour GAMT expression was significantly down regulated than 
WT mice correlating with decreased GSH levels at 24hour than WT mice (Fig. 3.4.6D 








Figure 3.4.6. Reduced mitochondrial complexes and increased ROS during injury 
phase following APAP300 treatment in p53KO mice. (A) Determination of 
mitochondrial DNA content. (B) Immunoblot of mitochondrial complexes (I), (II), (III), (V) 
and their regulatory transcription factors TFAM and NRF1 using total liver extracts from 
the respective groups. (C) Quantitative densitometry analysis of immunoblot of TFAM, 
Complex (I), (II) and (V). (D) Hepatic total glutathione levels at 24hour (upper panel) and 








p53KO mice exhibit increased inflammation after APAP treatment  
Our data on liver injury (serum ALT and H&E) and repair (PCNA staining and cell cycle 
markers) revealed that despite 3-fold higher liver injury, p53KO mice still recover at the 
same time as WT mice. We hypothesized that faster recovery despite very high injury in 
p53KO mice is due to higher inflammatory and proliferative signaling. Real time PCR 
analysis revealed that IL1β mRNA levels were induced at 1 and 12hour and declined by 
24hour post APAP300 in WT animals (Fig. 3.4.7A). Deletion of p53 resulted in further 
induction of IL1β mRNA levels at 1hour, 12hour and at 24hour it was significantly higher 
than WT mice (Fig. 3.4.7A). Likewise, IL10 mRNA levels were induced at 1 and 12hour 
and reduced by 24hour post APAP300 treatment in WT animals. Deletion of p53 
resulted in significant induction in IL10 mRNA at 1hour and 24hour after APAP300 
treatment (Fig. 3.4.7B). Previous studies have shown importance of both cytokines IL1β 
and IL10 in liver injury repair (Jaeschke, Williams et al. 2012). These data indicate that 







Figure 3.4.7. Deletion of p53 augments inflammatory and proliferative signaling 
during recovery phase following APAP300 treatment in mice. Real time PCR 
analysis of inflammatory genes (A) IL1β and (B) IL10. Western blot analysis of 
proliferative signaling consisting (C) p-AKT, AKT, p-ERK, p-EGFR, EGFR and (D) 
mTOR signaling, p-mTOR Ser2448, p-mTOR Ser2481, mTOR, p-p70S6K and p70S6K 













Enhanced liver regeneration in p53KO mice after APAP overdose 
Analysis of cell proliferation (PCNA) and cell cycle (Cyclin D1) showed that 
p53KO mice exhibit an initial delay followed by a robust liver regeneration leading to 
timely recovery despite three-fold higher liver injury. We further probed the mechanisms 
of this enhanced regenerative response in p53KO mice by measuring activation of key 
pathways involved in liver regeneration. Western blot analysis of AKT showed 
significantly higher and prolonged activation in p53KO after APAP treatment (Fig. 
3.4.7C). Likewise, deletion of p53 resulted in prolonged phosphorylation of ERK till 
24hour after APAP300 treatment. p53 is known to regulate EGFR at transcriptional level 
(Ludes-Meyers, Subler et al. 1996). Consistent with this we observed reduced 
expression of EGFR total protein in p53KO mice at all time points than WT mice. 
However, p53KO mice showed sustained EGFR phosphorylation following APAP300 
treatment (Fig. 3.4.7C). These data indicate that p53 deletion resulted in sustained 
proliferative signaling via AKT and ERK, which may enhance faster regeneration. 
Finally, we studied mTOR pathway, which plays a critical role in lipid 
homeostasis, cell proliferation, mitochondrial biogenesis, all major processes identified 
by our global transcriptomic analysis. p53 is known to inhibit mTOR through AMPK, 
PTEN, TSC2 expression (Feng, Hu et al. 2007), hence we hypothesized that deletion of 
p53 will increase activation of mTOR pathway. Western blot analysis of total mTOR 
protein showed no significant difference at all time points in both WT and p53KO 





groups however phosphorylation was prolonged in p53KO group (Fig. 3.4.7D). 
Phosphorylation of S6K - downstream target of mTOR was significantly higher and 
sustained in p53KO mice throughout time course than WT mice indicating higher and 
prolonged activation of mTOR pathway. 
 
3.5 DISCUSSION 
p53 is primarily known as a tumor suppressor because of it’s ability to inhibit cell 
proliferation. However, there is increasing evidence that p53 can regulate various cell 
responses such as migration, metabolism, redox balance, senescence, and stem cell 
reprogramming (Tyner, Venkatachalam et al. 2002, Muller, Vousden et al. 2011, 
Kenzelmann Broz and Attardi 2013, Menendez, Shatz et al. 2013, Aloni-Grinstein, 
Shetzer et al. 2014, Kruiswijk, Labuschagne et al. 2015). Recently Huo et. al. have 
shown protective role of p53 in APAP induced liver injury (Huo, Yin et al. 2017) but the 
exact mechanisms of this protection are not known. Our study strengthened this finding 
and further revealed various mechanisms by which p53 regulate injury progression as 
well as initiation of liver regeneration.  
The pathogenesis of APAP induced ALF can be divided into three phases 
including initiation of injury (formation of a reactive metabolite NAPQI and protein 
adducts) progression of injury (cellular signaling, oxidative stress, mitochondrial damage 
leading to cell death) and regeneration/recovery phase (cell proliferation, angiogenesis 





p53KO mice is similar till first 12 hours. However, liver injury progresses rapidly in 
p53KO mice resulting in 3-fold higher liver injury at 24 hours post APAP. These data 
indicate that p53 protects from progression of APAP-induced liver injury. Whereas the 
mechanisms of initiation of injury are well studied, the mechanisms of progression of 
APAP-initiated liver injury are not known. Our study indicates that p53 activation is a 
crucial component of protection against these mechanisms. 
We did not observe any difference in mechanisms of initiation of injury (CYP2E1, 
APAP adduct formation, GSH depletion or recovery etc.) (Reid, Kurten et al. 2005, 
Jaeschke and Bajt 2006), which is consistent with no difference in initial injury. 
Interestingly, p53KO mice exhibited reduced clearance of adducts from liver. APAP 
adduct formation has been shown to damage mitochondria and autophagy helps in 
removal of those adducts (Ni, McGill et al. 2016). Accumulating evidence supports p53’s 
role in facilitating autophagy under stress condition (Crighton, Wilkinson et al. 2006, 
Kenzelmann Broz and Attardi 2013, Kruiswijk, Labuschagne et al. 2015). It is plausible 
that reduced autophagy may have resulted in delayed adduct removal in p53KO mice.  
To determine the underlying mechanisms of increased injury and rapid repair in 
p53KO mice, we performed global transcriptomic analysis on three crucial time points 
namely 12, 24 and 48 hours after APAP treatment. Our transcriptomic analysis revealed 
disruption in metabolic homeostasis, increased inflammatory and proliferative signaling 
in p53KO mice. Consistently, p53KO mice exhibited higher and sustained steatosis, 
SREBP2 cleavage and prolonged hypoglycemia after APAP300 treatment correlating 





predisposing factors for increased risk and severity of APAP induced injury (Fromenty 
2013, Michaut, Moreau et al. 2014). Several studies in cancer cells have shown that 
p53 can limit glycolysis flux and promote fatty oxidation (Bensaad, Tsuruta et al. 2006, 
Kruiswijk, Labuschagne et al. 2015, Parrales and Iwakuma 2016). These data further 
indicate that p53 mediated metabolic homeostasis is disrupted in p53KO mice making 
them more vulnerable to APAP induced liver injury.  
Another aspect that can contribute to progression of APAP induced injury and 
lipid homeostasis is number of functional mitochondria (McGill, Sharpe et al. 2012).  Our 
data show that p53KO mice tend to have lower number of functional mitochondria as 
shown by lower mtDNA copy number and significantly reduced mitochondrial 
complexes till 24 hours. APAP overdose causes mitochondrial damage reducing 
capacity of liver to maintain homeostasis, and reduced mitochondrial complexes could 
further affect the homeostasis. Sustained steatosis along with less functional 
mitochondria in p53KO mice may have caused higher oxidative stress leading to 
depletion of hepatic GSH levels at 24 hours. Interestingly, we also observed deficiency 
in hepatic trans sulfuration pathway as demonstrated by reduced GAMT levels, a key 
enzyme in replenishing cellular cysteine pool required for GSH synthesis (Lu 2000, 
Schnackenberg, Chen et al. 2009). The decrease in GAMT in p53KO mice is consistent 
with the observation that it is a p53 target gene. Taken together, increased steatosis, 
higher oxidative stress and reduced GSH synthesis during progression phase results in 





Previous studies have shown that DAMPs released from necrotic cells after 
APAP overdose activate Kupffer cells (KCs) through TLR receptors leading to increased 
cytokine and chemokines production (Jaeschke, Williams et al. 2012). Pro-inflammatory 
cytokines and chemokines (IL1β, TNFα, MCP1 etc.) (Williams, Farhood et al. 2010) 
activate and recruit neutrophils and monocytes. Monocyte derived M2 macrophages get 
recruited in liver and secrete anti- inflammatory cytokines such as IL10. These activated 
phagocytes can remove dead cells from liver and initiate wound healing process 
(Bourdi, Masubuchi et al. 2002, Woolbright and Jaeschke 2017).  Interestingly, IPA 
analysis revealed significant activation of inflammatory pathways in p53KO mice. 
Indeed IL1β and IL10 cytokine expression was significantly higher in p53KO group than 
WT. It is plausible that higher liver injury results in higher IL1b secretion, which further 
stimulates increased inflammatory cell infiltration in the liver. Increased expression of 
pro- resolving cytokine IL10 may induce higher M2 macrophage activation, which will 
further aid in rapid recovery.  
Interestingly, despite very high injury, recovery in p53KO animals was similar to 
WT animals. PCNA and cell cycle protein data demonstrated delayed but rapid liver 
regeneration in p53KO mice indicating p53’s role in initiation of liver regeneration. This 
is a significant observation because several acute toxicity studies with APAP and other 
toxic chemicals including thioacetamide and CCl4 have shown that high injury results in 
extensive cellular stress and delay in liver regeneration (Mehendale 2005, Schmidt and 
Dalhoff 2005, Bhushan, Borude et al. 2013, Bhushan, Walesky et al. 2014). For 
example, previous study from our laboratory (Bhushan, Walesky et al. 2014) using 





non-regenerating dose of APAP) showed that resolution of injury after 600 mg/kg dose 
in WT mice was significantly impaired. In fact, ALT levels in the mice treated with 600 
mg/kg APAP, the non-regenerating dose in that study were almost equal to levels 
observed in p53KO mice treated with 300 mg/kg dose in this study. However, the 
p53KO mice still recovered by 48 hours in contrast to the WT mice with similar injury. 
These data suggest that deletion of p53 improves recovery by boosting the liver 
regeneration. 
Liver regeneration in response to injury has been shown to improve survival in 
rodent and human studies (Schmidt and Dalhoff 2005, Bhushan, Walesky et al. 2014). 
Several growth factor signaling pathways are known to stimulate liver regeneration. To 
study mechanism of rapid liver regeneration despite higher injury in p53KO animals, we 
looked at differential activation of several pro-mitogenic pathways involved in liver 
regeneration. These studies revealed significantly higher AKT, ERK and EGFR 
signaling in p53KO mice, all of which have been shown to stimulate hepatocyte 
proliferation and liver regeneration.  Additionally, we also observed that mTOR pathway 
was highly activated in p53KO mice than WT.  mTOR is known to inhibit autophagy 
process (Martina, Chen et al. 2012), increase lipid synthesis through S6K mediated 
SREBP cleavage, and increase cell proliferation (Laplante and Sabatini 2012). Previous 
studies have shown that p53 inhibits mTOR activity through direct transcriptional 
regulation of AMPK, TSC2, PTEN and IGFBP3 (Feng, Hu et al. 2007). It is plausible 
that during the injury progression phase following APAP overdose in WT mice; p53 
activation leads to up regulation of these negative regulators of mTOR. Deletion of p53 





regulation of autophagy mediated APAP adducts removal and disruption of lipid 
homeostasis leading to higher progression of APAP induced injury. It is also plausible 
that, during recovery phase, sustained mTOR and AKT activation may help faster liver 
regeneration in p53KO mice. Further studies are needed to delineate the exact role of 
mTOR signaling in p53KO mice after APAP. 
Taken together these data indicate that transient activation of p53 following 
APAP induced liver injury is beneficial to prevent progression of injury, however 
sustained activation of p53 may affect liver regeneration and recovery. Future studies 
using stage specific activation (during injury phase) or inhibition of p53 (during 
regeneration phase) are required to further establish function of p53 in regulating injury 
progression and regeneration.  Our studies have revealed novel pleiotropic role of p53 
in linking the injury progression response to liver regeneration and intervention of these 






































Drug-induced liver injury (DILI) is a significant clinical problem that also affects 
drug development process (Holt and Ju 2010). APAP mediated liver injury is the most 
prevalent cause of ALF in United States and many other countries (Ostapowicz, 
Fontana et al. 2002, Larson, Polson et al. 2005). Unlike several other drugs APAP 
induced toxic liver injury is not idiosyncratic reaction but occurs in dose-dependent 
manner that begins with mitochondrial dysfunction, ROS and extensive DNA 
fragmentation (Jaeschke 2015). Currently there are two main therapies for APAP-
induced ALF. The primary treatment for APAP overdose patients is intravenous 
administration of N-acetylcysteine (NAC), a precursor of GSH and works mainly via 
enhancing GSH replenishment. However, it is most effective when delivered within 8 
hours post APAP overdose. The majority of APAP-induced ALF patients are late 
presented reducing the effectiveness of NAC (Larson 2007, Fontana 2008, Lee, Larson 
et al. 2009). The other treatment option is liver transplantation for patients who progress 
to ALF. Unfortunately, transplantation has its own limitations including a lack of donor 
organs, high cost and life-long immunosuppression (Lee, Larson et al. 2009). 
Considering these extremely limited therapies at present, additional therapeutic options 
for APAP-induced ALF are urgently needed. Compensatory liver regeneration following 
DILI plays a critical role in survival (Mehendale 2005) (Jaeschke and Bajt 2006). 
Previous studies demonstrated that adequate stimulation of liver regeneration improves 
survival following APAP overdose (Mehendale 2005, Jaeschke and Bajt 2006, Apte, 
Singh et al. 2009, Bhushan, Walesky et al. 2014). Studies in ALF patients showed that 
increased liver regeneration indicated by elevated plasma α-fetoprotein (AFP) levels 





and Dalhoff 2005). Further, in theory, it may be possible to modulate liver regeneration 
even at later stages of APAP-induced liver injury. Thus, it is imperative to develop novel 
pharmacological agents that improve liver regeneration in patients of APAP-induced 
ALF. In response to APAP-induced liver injury, intricate signaling stimulates proliferation 
of healthy hepatocytes to replace the dead cells and results in recovery (Bajt, Knight et 
al. 2003, Apte, Singh et al. 2009, Bhushan, Walesky et al. 2014). However, such 
compensatory liver regeneration response is only activated up to a threshold dose. 
Following exposure to doses higher than the regenerative threshold dose, liver 
regeneration is inhibited, recovery is delayed and can lead to death (Mehendale 2005, 
Bhushan, Walesky et al. 2014). The most important aspect of liver regeneration is cell 
proliferation where quiescent healthy hepatocytes enter cell cycle, progress through 
complete cell cycle and produce two daughter cells. This cell division/ cell cycle is 
governed by various factors including presence of adequate growth factors (HGF, EGF), 
cytokines (IL6, STAT3), metabolic homeostasis, intact DNA and feedback from growth 
stimulating as well as growth inhibiting signaling (Michalopoulos 2007, Albrecht 2009).  
The mechanisms that drive cell proliferation after APAP-induced liver injury are not 
completely known. Especially, the mechanisms that inhibit cell proliferation at very high 
dose exposures are not known. It has been postulated that several factors including 
lack of proper signal transduction either due to decreased pro-mitogenic ligands or 
disruption of intracellular signaling, depleted energy due to mitochondrial damage and 







Cellular DNA is vulnerable to damage from various factors including endogenous (ROS, 
replicative stress) and environmental (chemicals, radiation) stresses.  Further, the risk 
of DNA damage increases during DNA replication phase of cell cycle (Saintigny, 
Delacote et al. 2001). Following surgical resection or chemical injury, hepatocytes 
undergo rapid proliferation to restore liver mass. That increases DNA replication 
associated risk of DNA damage (Saintigny, Delacote et al. 2001). Recent study has 
shown that genetic deletion of nucleostemin, a cell cycle modulator protein, in mice 
resulted in increased DNA double strand breaks in regenerating liver following PHX 
(Lin, Ibrahim et al. 2013). However, if DNA damage plays any role in liver regeneration 
following APAP induced liver injury remains unknown.   
Our laboratory has used an incremental dose model comprising a lower 
regenerative dose (300 mg/kg) and a higher non-regenerative dose (600 mg/kg) to 
determine the mechanisms behind inhibited regeneration at high APAP over dose 
(Bhushan, Walesky et al. 2014). Both doses cause severe liver injury and dose-
dependent activation of several proliferative pathways including EGFR, HGF and IL6 
and anti-proliferative p21 pathway. However, compensatory liver regeneration was 
prompted only at lower dose but was inhibited at higher dose despite more than 50% 
viable hepatocytes (Bhushan, Walesky et al. 2014). These observations would suggest 
activation of anti-proliferative signaling at higher dose that counteracted the highly 
activated proliferative pathway leading to inhibition of liver regeneration and mortality. 
This study also revealed that decreased liver regeneration after non-regenerative dose 
of APAP is not due to lack of viable cell mass as there are over 50% surviving 





that actively inhibits entry of these cells in cell cycle. The focus of the studies outlined in 
this dissertation was to study anti-proliferative mechanisms that can inhibit liver 
regeneration following APAP overdose. Understanding these mechanisms would 
provide insight into why some APAP induced ALF patients fail to spontaneously recover 
and need liver transplantation.  
We performed microarray analysis to delineate differentially regulated anti-
proliferative mechanisms using liver samples from both low and high dose of APAP 
treated mice. IPA analysis of microarray data revealed that DNA damage, DNA repair, 
replication, and cell cycle checkpoint pathways were significantly altered in lower dose 
animals as compared to higher dose. Consistently, APAP overdose caused DNA DSB, 
the most deleterious form of DNA damage, at both doses however it was sustained and 
prolonged only at the higher dose. More importantly, immunofluorescence detection 
revealed that hepatocytes surrounding necrotic zone exhibited DSB. Previous studies 
show that the hepatocytes that surround necrotic area undergo proliferation to replace 
dead cells that results in recovery from injury. Very interestingly, despite active growth 
factor (EGF, HGF) and cytokine (IL6, STAT3) mediated proliferative signaling at higher 
dose, hepatocytes appeared arrested either in G0 or in G1 phase of cell cycle. These 
data indicated to us that sustained DNA DSB could be hindering DNA replication and in 
turn liver regeneration at the higher, non-regenerative APAP dose. In response to DNA 
damage, the DDR pathway activates DNA repair process and p53, the DDR effector 
protein, arrests the cell cycle to provide time for DNA repair outcome (Sulli, Di Micco et 
al. 2012). DDR begins with detecting the DNA damage by sensor proteins such as 





proteins, it facilitates recruitment of DNA repair mediator and effector proteins. Our data 
shows rapid and sustained activation of PARP when DNA DSB was detected at lower 
regenerative dose. However, PARP activation was significantly reduced and delayed at 
higher APAP dose. This observation is consistent with a previous study demonstrating 
that higher PARP activation is not associated with increased liver injury following APAP 
toxicity (Cover, Fickert et al. 2005). In fact, PARP activation appears to prevent 
sustained liver injury possibly via facilitating DNA DSB repair. Cell cycle analysis in liver 
from mice given the non-regenerative APAP dose demonstrated that hepatocytes were 
arrested in G0 and/or G1 phase. DSB repair non-homologous end joining (NHEJ) 
remains active through all phases of the cell cycle while the homologous recombination 
(HR) pathway, operates during S and G2 phases. Therefore, we investigated differential 
regulation of NHEJ pathway in both doses. Moreover, de-phosphorylation of Tyr142 
residue of H2AX facilitates binding of repair proteins at DNA damage site (Cook, Ju et 
al. 2009, Xiao, Li et al. 2009). De-phosphorylation of H2AX Tyr142 and NHEJ repair 
protein expression was significantly deregulated at higher dose. These data collectively 
demonstrate that DNA DSB repair is impaired at higher dose due to reduced PARP 
activity (sensor) and repair protein expression (effector) leading to sustained DSB. 
Further investigation of DDR effector protein p53 revealed that p53 was activated at 
both low and higher dose of APAP, as DSB occurs at both doses. However, p53 
activation was significantly prolonged at higher dose correlating with sustained DNA 
DSB.  It is plausible that sustained DNA DSB resulted in prolonged p53 mediated 





Overall, this study has revealed that timely repair of damaged DNA regulates 
liver regeneration following APAP overdose. This is a first study to demonstrate the 
dose-dependent increase in DNA damage, dose-dependent inhibition of DNA repair and 
their connection with inhibition of liver regeneration and recovery after APAP overdose. 
It also indicates that DDR is a vital link connecting liver injury and initiation of liver 
regeneration.  Our work identified potential regulators in the DDR pathway that, if 
induced, could improve DNA repair and in turn, liver regeneration after APAP-overdose.  
These targets may be beneficial for potential development of regenerative therapies. In 
the future, induction of PARP activity and other DNA repair proteins in this model can be 
investigated in order to improve DNA repair following APAP toxicity.  
Our work using incremental APAP dose model demonstrated that lack of prompt 
DNA DSB repair resulted in p53 mediated cell cycle arrest and replicative senescence 
following higher dose of APAP when compared to a lower APAP dose. p53 was 
activated at both lower and higher doses but its activation at the lower dose was 
transient when compared to its activation at the higher dose. This suggested that p53 
activation regulates initiation of liver regeneration following APAP overdose.  In order to 
explore that, we investigated the role of p53 in APAP toxicity using WT and p53KO mice 
treated with the lower, APAP300 dose. Surprisingly, deletion of p53 resulted in 3-fold 
higher injury than WT animals. This observation was consistent with another study 
(Huo, Yin et al. 2017) indicating a previously unknown protective role of p53 in injury 
progression following APAP overdose. Deletion of p53 did not affect bioactivation of 
APAP and APAP adduct formation, which was reflected in similar initial injury in WT and 





following APAP300 dose was much higher than higher non-regenerative dose (Avg. 
peak ALT: 9500) give to WT animals in previous study. However, despite the very high 
injury, p53 KO mice showed full recovery from APAP exposure, presumably due to 
enhanced liver regeneration. In fact, deletion of p53 resulted in an initial delay in liver 
regeneration but once initiated p53 KO mice had significantly faster liver regeneration 
and complete recovery. These data collectively demonstrated that activation of p53 
protects injury progression and orchestrate initiation of liver regeneration after APAP 
toxicity.  
The role of p53 was further investigated using transcriptomic and molecular 
analysis. These studies revealed that deletion of p53 resulted in sustained activation of 
AKT and mTOR signaling, increased steatosis, decreased functional mitochondria, 
impaired adduct removal possibly through autophagy (Ni, McGill et al. 2016) and higher 
inflammation and cell proliferation. mTOR regulates inflammation, inhibit autophagy, 
increase lipid synthesis and cell proliferation (Laplante and Sabatini 2012, Martina, 
Chen et al. 2012). This observation is consistent with previous findings where p53 
inhibited mTOR by direct transcriptional regulation of mTOR inhibitors - AMPK, TSC2, 
PTEN and IGFBP3 (Feng, Hu et al. 2007). Our work demonstrated that deletion of p53 
led to higher and sustained activation of mTOR activity, which could result in down 
regulation of autophagy mediated APAP adducts removal and disruption of lipid 
homeostasis. GAMT is a p53 target gene and a key enzyme in replenishing cellular 
cysteine pool required for GSH synthesis (Lu 2000, Schnackenberg, Chen et al. 2009). 
Consistently, p53KO mice showed reduced GAMT levels indicating deficient GSH trans-





hepatic GSH levels but increased GSSG levels when compared to WT mice. These 
observations collectively demonstrated that p53 activation during injury progression 
phase could promote autophagy mediated adduct removal as well as lipid homeostasis 
by inhibiting mTOR activation, and GSH replenishment in WT mice. However, in the 
absence of p53, impaired adduct removal, increased steatosis, reduced GSH synthesis, 
and higher oxidative stress culminate in higher progression of injury.  
Interestingly despite very high injury deletion of p53 resulted in faster liver 
regeneration and complete recovery.  Based on IPA and cytokine (IL1β and IL10) 
expression data we demonstrated that p53KO mice have significant activation of 
inflammatory pathways. Consistent with previous studies, increased IL1β and IL10 
levels indicate activation and recruitment of neutrophils and monocytes. (Bourdi, 
Masubuchi et al. 2002, Woolbright and Jaeschke 2017). These activated phagocytes 
can remove dead cells from liver and initiate wound healing process by clearing path for 
regeneration. Moreover, deletion of p53 resulted in sustained activation of proliferative 
signaling such as mTOR, AKT, and ERK that correlated with delayed but rapid induction 
of PCNA positive cells. During recovery phase, higher monocyte recruitment as well as 
sustained mTOR and AKT activation may help faster liver regeneration in p53KO mice. 
Further studies are needed to delineate the exact role of mTOR signaling in liver 
regeneration after APAP. 
Collectively, our data indicate that in absence of p53-mediated mTOR inhibition, 
APAP-induced liver injury progresses during injury development phase and induces 





downstream targets as potential therapeutic targets to improve liver regeneration 
following APAP-induced ALF. In the future, studies using stage-specific activation 
(during injury phase) or inhibition of p53 (during regeneration phase) will be performed 
to further establish the function of p53 in regulating injury progression and regeneration. 
Studies with an mTOR activator or p53 inhibitor in non-regenerative dose will be done to 
elucidate effect on liver regeneration. Further, more extensive p53 binding repertoire will 
be studied using ChIP sequencing to obtain more complete picture of its function in 
APAP pathophysiology. 
CONCLUDING REMARKS  
The studies outlined in this dissertation provide insight into novel anti-proliferative 
mechanisms that can inhibit liver regeneration following APAP induced ALF. The 
treatment options for ALF are extremely limited and recently several studies 
demonstrated the power of improved liver regeneration as a plausible therapeutic 
option. However, the mechanisms that inhibit liver regeneration after APAP-induced 
ALF have not extensively studied. Our previous study using incremental dose model 
with regenerative and non-regenerative dose of APAP identified several pro-
regenerative pathways that improve recovery. Current work revealed the role of DNA 
damage as one of the anti-proliferative mechanisms that inhibit liver regeneration and 
recovery in non-regenerative dose. We demonstrated that APAP overdose caused DNA 
DSB leading to p53 mediated cell cycle arrest. However, timely repair of DSB releases 
cell cycle arrest and liver regenerates. On the contrary, failure to repair DNA damage 





regeneration at non-regenerative dose. Our work indicated that stimulation of DNA 
repair could be a viable approach to improve liver regeneration when spontaneous 
recovery is impaired following APAP toxicity.  Another approach could be to inhibit p53 
mediated replicative senescence. Indeed, our work demonstrated that deletion of p53 in 
mice enhances liver regeneration despite very high liver injury. Our work revealed a 
novel protective role of p53 in acute hepatotoxicity induced by APAP overdose. This 
suggests that transient activation of p53 following regenerative dose of APAP protects 
from injury progression. However, sustained p53 activation as seen in non-regenerative 
dose inhibits liver regeneration and recovery.  
Overall, our studies have identified mechanisms that inhibit liver regeneration 
affecting recovery, which provide insight into why some patients following APAP toxicity 
fail to recover spontaneously. The mechanisms of liver injury are well studied here we 
uncovered another player in injury progression following APAP overdose. Furthermore, 
our work demonstrated a very novel and critical mechanism that orchestrate liver injury 
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